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ABSTRACT
The goal of this project was to determine the genome organization, replication 
strategy and identification of the large envelope glycoprotein (Gl) gene of simian 
hemorrhagic fever virus (SHFV). This virus is the fourth member of the new virus family 
Arteriviridae
The 3' end of the RNA genome from the prototype isolate of SHFV was cloned and 
sequenced. This 6314 nucleotide (nt) sequence consisted of nine complete overlapping open 
reading frame (ORFs 2 ,2a, 3 ,4 ,5 ,6 ,7 ,8 , and 9). At the 5’ end of this sequence is a partial 
ORF, ORF lb, and the 3' end is a noncoding region. The sequence data showed that SHFV 
encodes three additional ORFs as compared to the other arteriviruses. The nine SHFV 3' 
ORFs were presumed to be translated from separate subgenomic mRNAs (sgRNAs) 
produced during virus replication. However, RT-PCR analysis using leader- and ORF- 
specific primers identified only eight sgRNA species. The sequence, 5 '-UCNUUAACC-3', 
was identified as the junction motif between the mRNA body and the 5 ' leader sequence. 
An ORF 2b-specific sgRNA was not detected.
The SHFV particle consists of two proteins, pl5 and p20, and at least two 
glycoproteins, p42 and p54. Endoglycosidase treatment of purified SHF virions showed that 
p42 and p54 were actually four separate peptides with molecular masses between 28 and 30 
kDa. Thus, the SHFV particle contains at least six structural proteins. In -vitro synthesis of 
the ORF 7 product resulted in a peptide with a molecular mass of 31 kDa; this mass 
increased to 52 kDa when the in vitro product was glycosylated. However, when the
xi
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glycosylated ORF 7 product was treated with endoglycosidase, the molecular weight of the 
peptide shifted to about 29,000. Immunoprecipitation results showed that the ORF 7 product 
was one of the SHFV GL proteins (p54). Four antigenic epitopes were identified using 
monoclonal antibodies generated by genetic immunizations of mice with the ORF 7 gene. 
One of these epitopes was identified as a virus neutralization site. The ORF 7 genes from 
two additional SHFV isolates were compared to the ORF 7 gene from the prototype isolate. 
No sequence difference was observed among these three isolates.
xii
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1. INTRODUCTION/ LITERATURE REVIEW
1.1 Pathogenesis and transmission of SHFV.
Simian hemorrhagic fever virus (SHFV) was first isolated in 1964 from diseased 
macaque monkeys in a quarantine facility at the National Institute of Health (NIH) after an 
epizootic of hemorrhagic fever within the colony. This initial epizootic resulted in the death 
o f223 of the 1050 animals in the facility (Palmer, et al., 1968). Concurrent with the NIH 
outbreak was a second epizootic at the Sukhumi Institute of Experimental Pathology and 
Therapy in the former Soviet Union. The same Indian supplier had shipped monkeys to both 
the NIH and Soviet Union facilities (Palmer, et al., 1968; Tauraso, et al., 1968).
Since the discovery of SHFV, many outbreaks have been reported in non-human 
primate captive colonies throughout the world. Additional outbreaks have been reported in 
macaque facilities in the United States in 1967,1972, and 1989, in Great Britain between 
1966 and 1969, and in Italy in 1992 (Plagemann, 1996).
The most recent SHFV outbreaks in the United States occurred in 1989. The first 
epizootic in that year was reported in the Primate Research Institute at the New Mexico State 
University in Alamorgordo; 400 macaques out of a population of approximately 2,000 died 
during this outbreak (Renquist, 1990). Later in that same year, three additional outbreaks 
were reported in Virginia, Pennsylvania, and Texas (Jahrling, et al., 1990). All affected 
monkeys were imported to these three facilities in the United States from the same Philippine 
supplier (Jahrling, et al., 1990). Most, but not all, monkeys involved in these latter 
outbreaks were co-infected with a second virus, Reston virus, which is a member of the
1
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genus Filovirus. Until the isolation of Reston virus, all filoviruses were considered highly 
lethal in humans. However, similar to SHFV, Reston virus does not appear to cause disease 
in humans (Jahrling, et al., 1990). The effect of SHFV on the Reston virus, and vice-versa, 
is not known. In 1992, another simultaneous SHFV/ filovirus outbreak was reported in 
Sienna, Italy. The monkeys affected were imported from the same Philippine supplier 
involved in the late 1989 epizootics in the United States (P. Jahrling, USAMRHD, Fort 
Detrick, personal communication).
SHFV induces a fatal hemorrhagic fever in rhesus {Macaco, mulatto), cynomolgus 
(Macaca fascicularis), stump-tail (Macaca speciosa), and bonnet (Macaca radiata) 
monkeys (Abildgaard, et al., 1975; Palmer, et al., 1968). Therefore, it is believed that all 
macaque monkeys are susceptible to SHFV disease. SHF in macaque monkeys progresses 
rapidly; macaques which were experimentally infected with SHFV developed clinical 
symptoms of disease within 1-2 days and died within 1-2 weeks post-inoculation 
(Abildgaard, et al., 1975). In the 1972 outbreak at the NIH facilities, 212 macaques were 
lost within a 12 day period (London, 1977). The onset of the disease in macaques consists 
of early fever, mild facial edema, anorexia, adipsia, dehydration, proteinuria, cyanosis, 
bloody diarrhea, nose bleeds, and occasional hemorrhages in the skin (Allen, et al., 1968; 
London, 1977; Palmer, et al., 1968). Pathological lesions consist of capillary-venous 
hemorrhages in many tissues. The lesions are often associated with evidence of vasodilation, 
stasis, and venous thrombosis. Thus, shock is suspected as the underlying causative factor 
of death (Gravell, et al., 1986a; Gravell, et al., 1986b).
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Although SHFV causes a fatal disease in monkeys within the genus Macaca, this 
virus can induce persistent infections in African monkeys such as patas monkeys 
(Erythrocebus patas), African green monkeys (Cercopithecus aethiops), and baboons (Papio 
anuibus and Papio cynocephalus) without inducing signs of clinical illness. Since viremia 
has been detected in these African monkey species, it was suggested that these species may 
be natural hosts for SHFV (Gravell, et al., 1986b; London, 1977). A survey of patas 
monkeys caught in the wild and imported from Africa to the United States indicated that 
49% of the 216 animals tested were persistently infected with SHFV as demonstrated by 
isolation of the virus from the blood of these monkeys (Gravell, et al., 1980a).
Although most SHFV isolates induce persistent infections in African monkeys 
without overt clinical signs, a spectrum of virus variants exist in nature which vary greatly 
in virulence for patas monkeys (Gravell, et al., 1986b). The more virulent strains replicate 
efficiently in macrophages of these monkeys causing an acute infection which is associated 
with high levels of viremia but which is eventually cleared by an effective antiviral immune 
response (Gravell, et al., 1986b). In contrast, the replication of the less virulent SHFV 
variants seems more restricted in patas monkeys to an as-of-yet unidentified cell type and the 
variants seem to be less immunogenic. Infection with these variants leads to an 
asymptomatic persistent infection associated with relatively low levels of viremia and a lack 
of formation of neutralizing antibodies (Gravell, et al., 1986a; Gravell, et al., 1986b). In 
spite of these differences in virulence in patas monkeys, all variants cause an acute, fatal, 
hemorrhagic disease in macaque monkeys (Gravell, et al., 1986a; Gravell, et al., 1986b).
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The mode of transmission of SHFV among African monkeys in the wild is unclear. 
No insect vector has been identified. The virus is not transmitted from persistently infected 
mothers to their offspring. Infection most likely occurs through open wounds and by biting, 
but sexual transmission has not been ruled out (Gravell, et al., 1980b).
No natural epizootics of SHFV in macaque monkeys have been reported. Obviously, 
natural transmission of SHFV from persistently infected African monkeys to macaque 
monkeys residing in Asia is excluded because of the geographical separation of these genera 
of monkeys. Usually, SHF disease develops in macaque monkeys shortly after they are 
imported to primate facilities from various Asian countries; however, when and how they 
become infected is unclear (Jahrling, et al., 1990). In fact, the source of virus in most of the 
past epizootics has not been proved. Because one epizootic had been attributed to injection 
of both macaque and African monkeys from a multidose vial with a common needle and 
syringe, the current hypothesis is that epizootics of SHF in captive macaque monkey colonies 
originates from accidental mechanical transmission of SHFV from persistently infected 
African monkeys (Gravell, et al., 1986a; London, 1977). With respect to the most recent 
SHFV epizootics in both the United States and Italy, in which all of the affected monkeys 
were shipped from the same Philippine supplier, contact of these macaques with persistently 
infected African monkeys either in the Philippines or during transit could not be ruled out 
(Jahrling, et al., 1990). In the laboratory, researchers were not able to infect various 
laboratory animals such as mice, rats, hamsters, and guinea pigs with SHFV (Tauraso, et al., 
1968). However, this virus was isolated from one mouse trapped during the New Mexico
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
epizootic in 1989 (P. Jahrling, personal communication). Therefore, the existence of 
alternate hosts as a source of infectious virus needs to be evaluated further.
Once illness becomes apparent, the disease spreads rapidly throughout the macaque 
colony. Although the mode of transmission of this virus between macaque monkeys is 
unknown, it is believed that SHFV can be spread among these susceptible animals by aerosol 
or direct contact (London, 1977).
1.2 SHFV replication in cell culture
All isolates of SHFV replicate in primary rhesus monkey peritoneal macrophage 
cultures. Rhesus monkey macrophage cultures are routinely utilized for isolation of new 
SHFV isolates. SHFV causes lytic infections in primary macrophage cultures; within three 
days after SHFV infection, rhesus monkey macrophages will round-up and lyse (Tauraso, 
et al., 1968). In fact, it has been proposed that the severity of cytopathic effect by SHFV on 
rhesus monkey macrophages may explain the disease and lethality of this virus in macaque 
monkeys (Gravell, et al., 1986b).
Along with primary monkey macrophage cultures, the prototype isolate of SHFV, 
LVR 42-0/M6941, will also replicate in the MA-104 (Gravell, et al., 1986a; Gravell, et al., 
1986b; Tauraso, et al., 1968) and the BSC-1 (Tauraso, et al., 1968) cell lines. Both of these 
cell lines were derived from African green monkey kidney cells. This SHFV isolate will also 
replicate in two other cell lines, CL-2621 and MARC-145 cells, which are subclones o f the 
MA-104 cell line (Plagemann and Moennig, 1992). Replication of SHFV in MA-104 cell 
cultures is rapid; release of progeny virus begins about 4 h post-infection (p.i.) reaching 
maximum titers around 24 h p.i. Cytopathic effects (CPE) become apparent in productively
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infected MA-104 cell cultures at 12-15 hr p.i. CPE begins as foci of highly re trac tile  
spindle-shaped cells which remain connected to each other by long, thin protoplasmic 
projections. As the CPE progresses, the cells become rounded and detach from the culture 
flask (Tauraso, et al., 1968). The CPE induced by the prototype isolate of SHFV on MA-104 
cells allows for the titration of this virus by the plaque assay method. Virus yields in 
infected cultures routinely reach 106 to 107 plaque-forming units/ml of culture fluid. Neither 
interferon production nor defective interfering particles were detected in infected MA-104 
cell cultures (Gravell, et al., 1980b). Interestingly, SHFV does not induce CPE in BSC-1 
cells. These cells continue to release virus without overt cytopathology (Tauraso, et al., 
1968).
13 Classification
Based on morphological characteristics, SHFV was initially classified within the 
virus family Togaviridae (Trousdale, et al., 1975). These characteristics include (1) an 
icosahedral nucleocapsid with a diameter of 25 nm, (2) a viral envelope surrounding the 
nucleocapsid conferring the entire virus particle a diameter of 50-60 nm, and (3) the lack of 
noticeable spike proteins protruding from the surface of the virion (Trousdale, et al., 1975). 
In 1985, the family Togaviridae was divided into two virus families, Togaviridae and 
Flaviviridae (Westaway, et al., 1985). Although morphologically similar, the togaviruses 
and flaviviruses differ in replication strategies, genome characteristics and organizations, and 
the membrane types used for budding from the host cell. Because it was thought that SHFV 
buds through the endoplasmic reticular membrane instead of the plasma membrane, as do
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the togaviruses, SHFV was removed from the family Togaviridae and reclassified as an 
unclassified member of the virus family Flaviviridae (Westaway, et al., 1985).
During the late 1980's and early 1990's, many viral genomes were being sequenced. 
Based on sequence data, it was determined that many viruses previously thought to be 
unrelated were genetically similar. As a result of genetic analyses and sequence data, the 
International Committee on the Taxonomy of Viruses (ICTV) created a new, free-standing 
genus Arteriviruses (Cavanagh, et al., 1994). This virus genus included equine arteritis virus 
(EAV), lactate dehydrogenase-elevating virus (LDV), porcine reproductive and respiratory 
syndrome virus (PRRSV), and SHFV. Most recently, the ICTV created a new virus order, 
Nidovirales which includes the families Arteriviridae and Coronaviridae (de Vries, et al., 
1997). The Arteriviridae is a monogeneric family containing the genus Arteri virus, while 
the bigeneric virus family Coronaviridae includes the genera Coronavirus and Torovirus. 
These two families within this virus order share similar genome organizations and replication 
strategies, although morphologically they are very different (de Vries, et al., 1997).
Aside from the physical properties, the arteri viruses share many common 
characteristics (reviewed in Plagemann and Moennig, 1992). First, all of these viruses 
establish asymptomatic, persistent infections in their natural hosts. Second, the replication 
cycles of all the arteri viruses are very similar and rapid. Third, macrophages are the primary 
target cell of these viruses in their natural hosts. This fact has been most clearly established 
for LDV. In the case of EAV, PRRSV, and SHFV it has not been resolved whether other 
types of cells in their respective hosts may also become productively infected. The 
replication of LDV and SHFV in vitro is highly restricted to primary macrophage cultures,
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except for the tissue culture adapted, prototype SHFV isolate. EAV is the most promiscuous 
of the arteri viruses in that it will replicate in many different cell lines, ie. VERO, BHK, and 
MA-104 cells.
1.4 Physical characteristics of SHFV
SHFV has been shown to be enveloped, pH sensitive, and relatively heat stable 
(Tauraso, et al., 1968). The virion particle is spherical with a diameter o f50-60 nm with a 
nucleocapsid diameter of 25 nm (Trousdale, et al., 1975). The sedimentation coefficient of 
the virion particles is 214 S while that of the nucleocapsid is 174 S (Sagripanti, 1984). The 
prototype SHFV isolate exhibits a buoyant density in sucrose density gradients of about 1.15 
g/cm3 and 1.18 g/cm3 in sodium-tartrate gradients (Trousdale, et al., 1975). The virus does 
not agglutinate erythrocytes of mice, rats, hamsters, guinea pigs, or chickens. No serological 
cross-reaction between SHFV and other arteri viruses has been detected (Plagemann and 
Moennig, 1992).
1.5 Arteriviral structural proteins
Viral structural proteins are proteins found in/on the mature virion particle. The 
structural proteins of EAV, LDV and PRRSV are similar in number and type. Arteri viruses 
generally contain a basic nucleocapsid protein (N) which forms the icosahedral capsid shell 
surrounding the viral genome, a nonglycosylated triple-spanning membrane protein (M) and 
one to two glycoproteins found embedded within the viral envelope (Gx, B, or Vp3). The 
glycoproteins generally smear into broad bands during separation by polyacrylamide gel 
electrophoresis (PAGE). The EAV particle contains at least two proteins and two 
glycoproteins: a 14 kD phosphorylated N protein; a 16 kDa M protein; Gs, which is a 25 kDa
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glycosylated envelope protein; and GL, a second glycosylated envelope protein between 30 
and 42 kDa (de Vries, et al., 1992). PRRSV contains a 15 kDa N protein, an 18 kDa M 
protein, and a 25 kDa glycosylated envelope protein (E) (Meulenberg, et al., 1995). The 
LDV particle is known to contain at least three structural proteins: Vpl, a 15 kDa N protein; 
Vp2, an 18 kDa M protein; and Vp3, a 24 to 44 kDa envelope glycoprotein.
The arteriviral envelope glycoproteins most probably represent the virus attachment 
protein because they are found in abundance on the outer surface of the viral envelope and 
neutralizing antigenic epitopes can be mapped to these proteins (reviewed in Plagemann, 
1996). The antibodies that neutralize EAV infectivity are all specific for the GL 
glycoprotein. In fact, six neutralizing monoclonal antibodies to EAV recognize a single 
epitope in the ectodomain of GL (Balasuriya, et al., 1995b). Similarly, several anti-LDV 
neutralizing monoclonal antibodies recognize the envelope glycoprotein (VP-3) of LDV 
(Faaberg and Plagemann, 1995).
Unlike the other arteri viruses, the number of structural proteins within the SHFV 
particles has been controversial for some years. Electropherograms by Trousdale, et al. 
(1975) suggested that the SHF virion consists of four structural proteins and two 
glycoproteins. These investigators did not report on the molecular weights of these proteins. 
Leon, et al. (1982) reported that the viral particle consists of four structural proteins with 
molecular masses of 10,12,16, and 25 kDa and a structural glycoprotein of 50 kDa; these 
results were obtained by SDS-PAGE and immunoprecipitation studies. A decade later, the 
same group found only three structural proteins within the SHF virion: a 12 kDa 
nucleocapsid protein (N or VP-1), a 16 to 18 kDa non-glycosylated envelope protein (M or
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VP2), and an envelope glycoprotein (E or VP-3) of about 50 kDa (Plagemann and Moennig, 
1992; Leon-Monzon, unpublished data). Most recently, Godeny, et al. (1995) determined 
the size and number of SHFV structural proteins. Four SHFV structural proteins were 
identified with apparent molecular masses of 15 (pl5), 20 (p20), 38-46 (p42) and 48-60 
(p54) kDa, as measured by SDS-PAGE analysis. pl5 was identified as the capsid (N) 
protein and the other three proteins were associated with the viral envelope. p20 was 
identified as the nonglycosylated membrane protein (M). The p42 (Gg) and p54 (Gl) bands 
represented glycoproteins which ran as smears by SDS-PAGE (Godeny, et al., 1995). It was 
not known whether these broad glycoprotein bands each represented one glycoprotein with 
different amount of glycosylation or different similar molecular weight glycoproteins which 
co-migrated.
1.6 Genomic characteristics of the arterivirnses
The arteri viruses are morphological similar to the togaviruses. However, in genome 
organization and replication strategy, these viruses are more similar to the coronaviruses 
(reviewed in Snijder and Spaan, 1995; de Vries, et al., 1997; Snijder and Meulenberg, 1998). 
The genomes of EAV, LDV and PRRSV have been sequenced and were shown to be 12.7 
kb (den Boon, et al., 1991a), 14.2 kb (Godeny, et al., 1993) and 15.1 kb (Meulenberg, et al., 
1993b) in length, respectively. The genomes of these viruses encode eight open reading 
frames (ORFs), designated ORFs la, lb, 2 ,3 ,4 ,5 ,6  and 7 (Fig. 1) according to conventional 
nomenclature (Cavanagh, et al., 1990).
The 5' terminal two-thirds of the viral genomes are taken up by two large ORFs, la 
and lb . The products of these ORFs are translated from the frill length genome RNA. The
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translation of ORF lb, which is in a -1 reading frame relative to ORF la, requires a 
ribosomal frameshift immediately before ORF la termination (den Boon, et al., 1991a). This 
frameshift event occurs because of the presence of a “slippery sequence”, the actual 
frameshift site, and a downstream RNA pseudoknot structure at the ORFs la-lb junction 
(den Boon, et al., 1991a). Although these frameshift signals have been identified within the 
EAV (den Boon, et al., 1991a), LDV (Godeny, et al., 1993) and PRRSV (Meulenberg, et al., 
1993b) genomes, the functionality of these signals has only been demonstrated for EAV (den 
Boon, et al., 1991a). ORFs la  and lb encode polyproteins which are post-translationally 
cleaved into the viral nonstructural proteins, ie. the viral polymerase, proteases and other 
proteins necessary for viral replication. Four highly conserved peptide domains are found 
within the ORF lb gene (Fig. 1); these domains are conserved among all members of the 
virus order Nidovirales (de Vries, et al., 1997). The first domain, Domain 1, encodes the 
viral polymerase motif. Although most viral RNA-dependent RNA polymerases contain the 
typical -GDD- amino acid sequence, members of the order Nidovirales possess an -SDD- 
sequence (de Vries, et al., 1997). Domain 2  contains a metal binding protein motif and 
domain 3 is a helicase motif. Domain 4, also known as the carboxy terminal domain, 
encodes a peptide motif which is only found in viruses within the order Nidovirales. The 
function of domain 4 remains undetermined but has been postulated to play a role in 
subgenomic mRNA synthesis (den Boon, et al., 1991a).
The remaining one-third of the arteriviral genomes, downstream of ORF lb, encodes 
ORFs 2 through 7 (Fig. 1) which usually overlap their respective adjacent 5' ORFs. Using 
the EAV terminology, ORFs 2, 5, 6 and 7 of EAV, LDV and PRRSV encode the small
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Figure 1: Schematic representation of the genome organization (A) and replication 
strategy (B) of EAV, the prototype arterivirus. All ORFs and sgRNAs are drawn 
approximately to scale. The ORFs are numbered la  through 7 and the sgRNAs are 
numbered RNA 1 through 7. The locations of the conserved domains in ORF lb  are 
shown in black and are labeled d l (replicase), d2 (metal-binding), d3 (helicase), and d4 
(carboxy-terminal).
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envelope glycoprotein (Gg), the large envelope glycoprotein (G [), the membrane protein (M) 
and the nucleocapsid protein (N) (de Vries, et al., 1992; Faaberg and Plagemann, 1995; 
Godeny, et al., 1990; Mardassi, et al., 1996; Meulenberg and Petersen-den Besten, 1996; 
Meulenberg, et al., 1995). It has been reported that ORFs 3 and 4 of PRRSV encode 
additional viral structural glycoproteins (vanNieuwstadt, et al., 1996). However, the LDV 
ORF 3 and EAV ORF 4 products have not been detected in purified virus particles (de Vries, 
et al., 1997; Faaberg and Plagemann, 1997).
The SHFV genome is composed of a 49 S (5.5 X 106 Da) single-stranded RNA 
molecule estimated to be approximately 15,000 nucleotides (nt) in length (Sagripanti, 1984). 
The genome exhibits positive polarity and is polyadenylated at the 3' terminus (Sagripanti, 
1985). A type I cap, m7G(5')ppp(5')Am, is found at the 5' terminal end of the viral genome 
(Sagripanti, et al., 1986). The first 954 nt sequence located at the 3' end of the SHFV 
genome was reported previously (Godeny, et al., 1995). This sequence included a 76 nt 3' 
noncoding region and contained one partial and two complete ORFs. Both of the complete 
ORFs overlapped their adjacent 5' ORFs (Godeny, et al., 1995). Similar to the other 
arteriviruses, the SHFV N protein mapped to the ultimate 3' ORF and the M protein mapped 
to the penultimate ORF (Godeny, et al., 1995).
1.7 Arteriviral subgenomic mRNAs
As discussed above, the EAV, LDV and PRRSV ORFs la and lb products are 
translated from genome-length, viral mRNA. The remaining 3' ORFs are translated from 
a set of six to seven subgenomic mRNAs (sgRNAs) which are produced during virus 
replication. These sgRNAs are co-terminal and nested at the 3' terminal end of the genome
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(Fig. 1) (Kuo, et al., 1992; Meulenberg, et al., 1993b; van Berio, et al., 1982). Although 
most of the sgRNAs are polycistronic, only the 5'-most ORF is translated from each sgRNA. 
Each of the sgRNAs is polyadenylated at the 3 ' end and contains a 5' leader sequence (Kuo, 
etal., 1992; Meulenberg, etal., 1993b; van Berio, etal., 1982). The leader sequences, which 
are approximately 200 nts in length and are encoded at the 5' terminus of the viral genome, 
are thought to be added to each sgRNA by a leader-priming mechanism (Snijder and 
Meulenberg, 1998). The 5' leader sequence is joined to the sgRNAs at junction or intergenic 
sequences (Snijder and Meulenberg, 1998; Snijder and Spaan, 1995). These junction 
sequences are highly conserved among the sgRNAs of a specific virus and are similar among 
all of the arteriviruses sequenced to date. The junction sequences have been identified as 5' 
-UCAAC(U/C> 3' for EAV (den Boon, et al., 1996), 5' -U(A/G)(U/A)AACC- 3' for LDV 
(Godeny, etal., 1993; Kuo,etal., 1992), and5' -GNUNAACC- 3' for PRRSV (Conzelmann, 
et al., 1993; Meulenberg, et al., 1993a).
Six sgRNAs have been detected during SHFV replication by Northern blot analyses 
(Godeny, et al., 1995; Zeng, et al., 1995). These polyadenylated SHFV sgRNAs (Zeng, et 
al., 1995) were shown to be approximately the same length as the sgRNAs of other 
arteri viruses (Godeny, et al., 1995). Each of the SHFV sgRNAs was shown to contain a 202 
nt, noncoding, 5' leader sequence derived from the 5' end of the viral genome (Zeng, et al., 
1995). Similar to the other arteri viruses, the junction sequence between the 5' leader 
sequence and the sgRNA body was determined as 5' -U(C/U)AACC- 3' for the two smallest 
SHFV sgRNAs, RNAs 6 and 7 (Zeng, et al., 1995).
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1.8 Overview of the dissertation
Because tittle is known about the molecular characteristics of SHFV as compared to 
the other arteri viruses, the main thrust of this project is to characterize the virion particle. 
Emphasis is placed on determining the number of glycoproteins in the viral envelope, 
sequencing the SHFV structural protein ORFs, mapping the large envelope glycoprotein on 
the viral genome, and evaluating the number of antigenic epitopes on that glycoprotein. The 
sgRNA junction sequences are also determined.
The arteri viruses are emerging viruses. Although they have only been identified in 
four host species, other animal species, including humans, may harbor unidentified 
arteri viruses. EAV and PRRSV are important pathogens to the horse racing and pork 
producing industries, respectively, leading to great economic losses. Much effort and 
expense is currently being applied to controlling these virus infections. The data generated 
from this project could be used for the diagnosis and prevention o f SHFV in primate 
colonies. Further, some of this data might also be extrapolated to the other related 
arteri viruses and aid in our understanding of their replication processes.
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2. MATERIALS AND METHODS
2.1 Cell culture and media
MA-104 cells (African green monkey kidney cells) were obtained from Whittaker 
Bioproducts, Inc. (Walkersville, MD) and Hela cells (Human epithelioid carcinoma cells) 
were obtained from Dr. C.J. Gauntt (University of Texas, Health Science Center, San 
Antonio, TX). These cells were cultured in complete minimal essential medium (MEM) 
supplemented with 0.056% NaHC03 (Gibco BRL, Gaithersburg, MD), 2 mM L-glutamine 
(Sigma Chemical Co., S t Louis, Mo), 50 fzg/ml of gentamycin sulfate (Gibco BRL), and 
with 2% fetal calf serum (FCS; Sigma Chemical Co.) in a 5% C02 humidified environment 
at 37°C. Upon confluency, cells lines were washed once using phosphate-buffered saline 
(PBS, pH 7.4) and treated with 0.025% trypsin in versene salts (Sigma Chemical Co.) to 
detach cells. After all the cells detached from the tissue culture flask, they were diluted with 
the above medium, and used to seed additional tissue culture flasks (175 cm2) with 
approximately 5 x 106 cells. Stocks of these cell lines were pelleted at 1000 rpm for 5 min, 
resuspended in the FCS with 10% DMSO at a concentration of 5 X 106 cells/ml and frozen 
in a KRYO-10 cell freezer (Planar Biomed Products LTD., Sunbury-On-Thames, England) 
as directed by the manufacturer. Frozen cell stocks were stored in liquid N2 until needed.
The mouse myeloma cell line, P3x63Ag8.653 (X63 cells), were obtained from Dr. 
R. Truax (Cell and Organ Culture Laboratory, School of Veterinary Medicine, Louisiana 
State University). The X63 cells were cultured in complete RPMI-1640 media (RPMI; 
Gibco BRL) supplemented with 10% FCS, 50 //g/ml gentamycin sulfate, 2 mM L-glutamine
17
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and 10% FCS. Fifteen /zg///l 8-azagnanine (Sigma Chemical Co.) was added to the media 
to prevent the cells from reverting from hypoxanthine-guanine phosphoribosyl transferase 
(HGPRT)-negative to HGPRT-positive cells. The X63 cells were maintained in a log phase 
by passing the cells every three days. Three days prior to cell fusion, the cells were passaged 
in the above medium without 8-azaguanine in order to remove residual drug from the 
cytoplasmic pool.
Primary monkey macrophages were prepared from rhesus monkey blood which was 
obtained from the Tulane Regional Primate Research Center (Covington, LA). Whole blood 
was centrifuged at 800 X G for 15 min and the plasma layer was aspirated off. The bufiy 
coat was transferred into a new tube and mixed with cold PBS. The mixture was then layered 
atop Histopaque (Sigma Chemical Co.) and centrifuged at 800 X G for 40 min. The cells at 
the PBS-Histopaque interface were transferred into a fresh tube and washed three times with 
cold PBS by centrifugation at 800 X G for 10 min. After washing, the pellet was 
resuspended in RPMI medium without FCS and transferred into tissue culture flasks. The 
macrophages were attached to the flasks by incubation at 37°C for 6 hr with shaking every 
30 min. Then the attached macrophages were washed with RPMI medium without FCS 
three times and incubated in complete RPMI medium containing 500 U/ml recombinant 
human macrophage-colony stimulating factor (rM-CSF; Cellular Products Inc., Buffalo, NY). 
2.2 Viruses
The prototype SHFV isolate (LVR 42-0/M6941) was obtained from the American 
Type Culture Collection (ATCC, Rockville, MD). Virus was adsorbed to MA104 cells at 
a multiplicity of infection (MOI) of 0.1 plaque forming units (PFU)/cell for 45 minutes at 
room temperature. The cells were then washed and incubated in complete MEM containing
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2% FCS. The supernatant fluid was harvested after 48 hr in a 5% COj, humidified incubator 
at 37°C and clarified by centrifugation at 2,000 rpm for 5 minutes followed by a second 
centrifugation at 10,000 rpm for 20 minutes. For stock virus, the clarified supernatant fluid 
was aliquoted, frozen, and stored at -70°C until needed.
Two other isolates of SHFV, 1-621 and Ph0080, were obtained from Dr. P. Jahrling 
(USAMRHD). These isolates were obtained from the 1989 epizootic in New Mexico. 1-621 
was isolated from the liver of a monkey after it was experimentally inoculated with a liver 
homogenate from a mouse trapped during the outbreak. Ph0080 was a splenic homogenate 
from an infected rhesus monkey. These isolates were cultured in primary monkey 
macrophages in RPMI media using the same procedure as described above for the prototype 
SHFV isolate in MAI04 cells..
When purified SHFV was needed, the following procedure was used. The virus- 
containing supernatant fluid was harvested 48 hr p.i. from infected MA104 cells and clarified 
as above. The virus was concentrated by precipitation with 8% polyethylene glycol (PEG 
8000; Sigma Chemical Co.). After pelleting by centrifugation at 10,000 rpm for 30 min at 
4°C, the virus was resuspended in TN buffer (10 mM Tris-HCl and 50 mM NaCl, pH 7.6) 
and centrifuged through a 0.5 M to 2.0 M continuous sucrose gradient in TN buffer at 24,500 
rpm for 16 hr. Gradient fractions were collected using an Isco fractionator (Isco Inc., 
Lincoln, Nebraska). Peak fractions containing the virus were pelleted by centrifugation of 
30,000 rpm at 4°C for 2 hr.
Virus titers were obtained by the standard plaque assay method (Hierholzer and 
Killington, 1996) using MA104 cells. Ten-fold dilutions of the virus were attached to 
MA104 cell monolayers in the 12-well tissue culture plate (Costar Corp., Cambridge, MA)
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for 45 min. The liquid was then removed and the cells were overlaid with nutrient medium 
which consisted of complete MEM containing 2% fetal calf serum and 1% low melt agarose 
(Amresco Inc., Solon, Ohio). After 36 hr at 37°C in a 5% COz hum idified  chamber, the 
overlay medium was stained with neutral red dye (Sigma Chemical Co.) for 4-8 hr, and the 
virus plaques were counted. All plaque titrations were done in duplicate and were reported 
in plaque-forming units per ml (PFU/ ml).
35S-Iabeled viral proteins were prepared by metabolic-radiolabeling of SHFV 
particles. Two hours p.i., the MAI04 growth media was replaced with complete MEM 
lacking cysteine and methionine and containing only 2% fetal bovine serum. One hour later, 
the medium was supplemented with 80 uCi/ ml 3SS- translabel cysteine and methionine/ ml 
(ICN, Irvine, CA). Radiolabelled virus particles were purified as described above. For 35S- 
labeled SHFV cell lysates, the infected cells were washed two times with PBS at 16 hr p.i. 
and lysed with lysis buffer containing 50 mM sodium phosphate (pH 8.0), 0.5% (w/v) 
sodium deoxycholate, 1% (v/v) Nonidet-P40 (NP-40), 10 mM EDTA, and lug/ ml each of 
leupeptin, aprotonin, and pepstatin A (Sigma Chemical Co.).
Viral proteins were also metabolically radiolabeled with l4C-amino acids and3 H- 
¥
myristic acid and viral RNA was radiolabeled with 3H-uridine as described above. However, 
for I4C radiolabeling, the virus growth medium was replaced with complete MEM with one- 
tenth amino acids containing 2% FCS and 20 uCi/ ml l4C-amino acid mixture (Amersham 
Life Science, Inc., Arlington Heights, EL) at 3 hr p.i. For 3H-myristic acid labeling, virus 
growth medium was replaced with complete MEM containing 2% FCS and 100 pCi/ ml 
[9,10(n)-3H] myristic acid (Amersham Life Science, Inc.) at 3 hr p.i. The SHFV genomic 
RNA was also metabolically radiolabeled in MA104 cells. SHFV was grown in these cells
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as described above except that SO ^Ci/mi [5,6-3H] uridine (Amersham Life Science, Inc.) 
was added to the media at 3 hr p i. Regardless of isotope used, all radiolabeled SHFV was 
purified as described above.
23  Neutralization assay
The standard virus neutralization assay (Chemesky, 1996) was performed with some 
modifications. Briefly, serial dilutions of anti-SHFV sera, which had been heat-inactivated 
at 56°C for 30 min to inactivate serum complement, was mixed with equal volumes of 
SHFV at 103 PFU/ ml. The mixture was incubated at 37°C for 30 min to allow the 
antibodies in the sera to attach to the virus particles. Then, the mixture was added to 
confluent MAI 04 cell monolayers in 12-well tissue culture plates at 50 PFU/ ml and the 
virus was allowed to attach to the cells. The standard plaque assay procedure as described 
above was then followed. Plaque numbers in wells containing the virus-anti sera mixtures 
were compared to those in wells containing virus only; a 50% reduction in plaque number 
was considered positive for virus neutralization.
2.4 Viral RNA isolation
The viral RNA was isolated from purified virus particles using the RNase TM Total 
RNA Kit (Qiagen, Inc., Chatsworth, CA) as instructed by the manufacture. The RNA 
samples were ethanol precipitated and stored at -70 °C until needed. For intracellular RNA 
isolation, MA104 cells were infected with the prototype isolate of SHFV, the infected cells 
were lysed with lysis buffer at 20 hr p.i. and the intracellular RNA was isolated using the 
RNase TM Total RNA K it
Special precautions were taken to prevent RNase digestion of viral RNA during the 
isolation procedures and use (Sambrook, et al., 1989). All glassware used in RNA
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experiments was baked at 200°C for 6 hr prior to use. RNA solutions were treated with 0.5 
ml/1 diethyl pyrocarbonate (DEPC) overnight prior to autoclaving. RNA concentrations were 
determined by optical density using a Du 60 Spectrophotometer (Beckman Inc., Palo Alto, 
CA).
2.5 Cloning of the 3 ' end of the SHFV genomic RNA
The 3' end of the SHFV RNA genome was cloned as previously described (Godeny, 
et al., 1995). A synthetic oligonucleotide DNA primer was synthesized in Gene Lab at the 
School of Veterinary Medicine, Louisiana State University and annealed to purified genome 
RNA from the prototype isolate of SHFV in 10 mM Tris, pH 7.2,16 mM KC1 at 100°C for 
3 m in. The primer sequence, 5'-CCCTTCCATTGAGTATG-3', is complementary to 
nucleotides 449- 465 from the 3' terminus of the SHFV genome (Godeny, et al., 1995). The 
annealing mixture was slow-cooled (more than 30 min) to room temperature prior to the 
addition of 20 mM Tris, pH 8.3, 16 mM KC1, 3.2 mM MgCl2, 80 /zM of each of the four 
deoxynucleotides and 0.17 mM dithiothreitol (DTT). For detection purposes, 20 /j.Ci of 
deoxyadenosine 5'-[a-32P] triphosphate (dATP; Amersham Life Science Corp.) was added 
to the reaction mixture. Avian myeloblastosis virus (AMV) reverse transcriptase (25 U; 
Pharmacia Biotech Inc., Piscataway, NJ) was added to the reaction mixture to synthesize 
cDNA copies of the viral RNA at 42°C. After 1 hr, the RNA was phenofrchloroform 
extracted and ethanol precipitated.
The second cDNA strand was synthesized at 12°C in a reaction mixture containing 
20 mM Tris, pH 7.5,5 mM MgCl2, 10 mM NH4(S04)2, 10 mM KC1,200 /zM of each of the 
four dNTPs, 5 U £  coli DNA polymerase I, 1 U RNase H and 2 U T4 DNA ligase. 
Following a 1 hr incubation, the temperature was increased to 22°C for an additional hour.
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The mixture was heated to 70°C for 1 min, 5 U T4 polymerase was added, and further 
incubated for 20 min at 37°C. The reaction was stopped by the addition of 0.25 M EDTA. 
The cDNA was phenohchloroform extracted twice and precipitated with ethanol. The 
precipitates were resuspended in water and the EcoRI sites within the SHFV DNAs were 
methylated using 6 pM S-adenosyl methionine and 2 U EcoRI methylase (New England 
Biolabs, Inc., Beverly, MA) in the supplied buffer, overnight at 37°C. The methylated DNA 
was then phenohchloroform extracted twice, ethanol-precipitated, and pelleted. Next, 5'- 
phosphorylated EcoRI linkers (Pharmacia Biotech) were added to both ends of the double 
stranded DNA at 14°C for 5 hr with T4 DNA ligase (New England Biolabs, Inc.) in ligase 
buffer which was supplied by the manufacture. The ligated cDNA was heated to 100°C for 
10 seconds and the linkers were then digested overnight with 120 U of restriction 
endonuclease EcoRI (New England Biolabs, Inc.) in the buffer supplied by the manufacture 
at 37°C. The cDNA was fractionated on a Sepharose 4B column (Sigma Chemical Co.) in 
0.2 M Tris, pH 7.4, 0.1 mM EDTA to remove free nucleotides and small oligonucleotide 
fragments (<200 nt in length). Fractions from the column were collected and counted in a 
beta scintillation counter. Fractions containing peak levels of incorporated radioactivity were 
pooled and ethanol-precipitated.
The pelleted cDNA was inserted into the EcoRI-digested pGEM7ZF+ plasmid vector 
(Promega Corp. Madison, WI) according to the manufacturers instructions by incubating at 
room temperature overnight with 4 U T4 DNA ligase and ligase buffer. The recombinant 
plasmids were extracted with phenohchloroform and ethanol-precipitated. The DNA pellet 
was washed with 70% ethanol and resuspended in water.
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E.coli strain, JM109 (Promega Corp), in exponential growth phase, was pelleted, 
resuspended in TFB (10 mM 2-[N-morphoIino]ethanesulfonic acid, 45 mM MnClj, 100 mM 
KC1 and 3 mM hexamminecobolt chloride), and treated on ice with 0.33% (v/v) DMSO and 
30 mM DTT prior to transformation. The recombinant pGEM plasmids were added to the 
treated bacterial cells. The cells were chilled on ice for 30 min, heat-shocked at 42 °C for 90 
seconds and then again chilled on ice for 2 min. SOC medium (2% tryptone, 0.5% yeast 
extract, 10 mM NaCI, 2.5 mM KC1,10 mM MgCl̂ , and 20 mM glucose) was added and the 
cells were incubated for 1 hr at 37°C on a shaker (220 rpm). The cells were next pelleted 
at 1600 rpm for 10 min, resuspended in SOC media and plated on LB agar plates (1% 
tryptone, 0.5% yeast extract, 1% NaCI, pH 7.0, 1.5% agar) (Sambrook, et al., 1989) 
containing 50 ^ig/ml ampicillin, 5 fxg/1 IPTG and 0.33 mM X-gal. Bacterial plates were 
incubated at 37°C overnight. Plasmid-transformed E. coli containing the cloned SHFV 
cDNA were screened for p-galactosidase gene expression (Close, et al., 1983). White 
colonies were picked, amplified in LB broth containing 50 //g/ml of ampicillin and frozen 
at -70°C until screened for SHFV specificity.
The DNA clones were screened for SHFV specificity by Northern blot analysis 
(Krumlauf, 1996) using riboprobes (Sambrook, et al., 1989). Riboprobes were synthesized 
in vitro using a previously isolated SHFV clone, dt-9. The dt-9 clone contained the first 806 
nt from the 3' terminus of the SHFV genome inserted into the pGEM plasmid vector 
(Godeny, et al., 1995). The plasmid DNA was extracted from E. coli using the Quantum 
Prep Plasmid Miniprep Kit (Bio-Rad Laboratories, Hercules, CA) and cut with the restriction 
endonuclease Hind HI (New England BioLabs, Inc.) overnight at 37°C. The linearized DNA
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
25
was extracted with phenolxhloroform. After ethanol precipitation, the DNA was washed in 
70% ethanol, dried, and resuspended in water containing 4 U RNasin/^1 (Promega Corp.).
The radiolabelled riboprobes were prepared using the Riboprobe System-T7 kit 
(Promega Corp.). Briefly, the DNA was denatured at 70°C for 10 min and then kept on ice. 
1 (j.% of this sample was mixed with 80 mM Tris (pH 7.5), 12 mM MgCl2, 10 mM DTT, 80 
U RNasin, 10 /xM UTP, 0.5 mM each of ATP, CTP, GTP, 20 U T7 RNA polymerase, and 
50 /zCi [a- 32P] uridine triphosphate (Amersham Life Science, Inc.). The reaction was 
incubated at 37°C for 90 min and then 1 /xg of RNase-free DNase was added to the mixture 
and incubated for an additional 15 min. The probe was extracted with phenolxhloroform 
and precipitated with ethanol. The pelleted probe was resuspended in 100 /xl 2.5 mM 
piperazine-N,N' -bis[2-ethanesulfonic acid], pH 6.4 (PIPES; Sigma Chemical Co.) and 
counted in a scintillation counter.
The DNA clones to be screened were extracted from amplified colonies of E. coli in 
LB broth using the Quantum Prep Plasmid Miniprep Kit Portions of the minipreps were 
mixed with 10X SSC (1.5 M NaCI, 0.15 M Na citrate, pH 7.0), denatured by heating to 
100°C for 10 min, and blotted onto a nitrocellulose membrane (Bio-Rad Laboratories, 
Hercules, CA), The membrane was air-dried, baked at 80 °C for 2 hr, and then stored at room 
temperature until needed.
The dotted DNA membrane was rinsed in DEP-treated water and incubated with 
hybridization solution consisting of 50% formamide, 5X Denhardt's solution (0.1% bovine 
serum albumin (BSA), 0.1% (w/v) ficoll, 0.1% (w/v) polyvinylpyrrolidine (Sigma Chemical 
Co.)), 5X SSPE (0.9 M NaCI, 20 mM sodium phosphate, pH 6.8, and 5 mM EDTA), 0.1% 
SDS, 200 /xg! ml salmon sperm DNA, and 200 fxgf ml tRNA. The membrane was
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
26
prehybridized for 4 hr at 45 °C. The RNA probe (105 cpm) was then added to the 
hybridization mixture and incubation was continued overnight at 65 °C. The membrane was 
washed at room temperature for 20 min in IX SSC and 0.1% SDS followed by three washes 
in 0.2X SSC and 0.1% SDS at 68°C for 20 min each. Specific SHFV blots were visualized 
by autoradiography.
2.6 Nucleotide sequencing
Minipreps of the plasmid DNA containing the desired SHFV insertions were made 
using the Quantum Prep Plasmid Miniprep Kit The SHFV cDNAs were sequenced by the 
dideoxy chain termination method(Sanger, et al., 1977) using Sequenase® (T7 Polymerase) 
supplied in the Sequenase™ Version 2.0 DNA Sequencing Kit (United States Biochemical 
Corp., Cleveland, OH). Synthetic oligonucleotides, either homologous to the M l 3-reverse 
sequence site or complementary to the M13-universal sequence site on the plasmid vector 
were used to prime the DNA templates. Separate sequencing reactions were initiated from 
each end of the DNA insert, but on different DNA strands, until an overlapping 
complementary sequence was obtained. For long SHFV clones (more than 600 nt), synthetic 
oligonucleotide primers (Gene Lab) complementary to a selected 18 to 24 nt region, were 
used to prime internal initiation sequencing reactions to "walk along" the entire sequence. 
In order to produce the majority sequence of the viral genome, multiple clones for each 
nucleotide were sequenced. If more than one clone was not available for a particular 
nucleotide, then the nucleotide was determined by direct sequencing of the SHFV RNA 
genome.
Viral RNA was sequenced directly by a modified dideoxy chain termination method 
(Sleigh, et al., 1981; Wunner, et al., 1985) using the RT- RNA Sequencing Kit according to
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the manufacturers instructions (U.S. Biochemical Corp.). Briefly, the synthetic 
oligonucleotide primer of choice (0.4 f-ig/ /d) was annealed to the viral RNA at 90°C for 1 
min in hybridization buffer (20 mM Tris, pH 7.5,10 mM MgCl2, 10 mM NaCI and 0.2 mM 
DTT) with 40 U RNasin (Promega Corp) and then placed in a 40 °C water bath for 5 min. 
The annealed RNA template reverse-transcribed in hybridization buffer containing 1.4 /ug 
actinomycin D, 10 /zM each of dGTP, dTTP, dCTP, 1 fjM dATP, 10 pCi 32P-dATP and 1.5 
U reverse transcriptase at 40°C for 5 min. Chain termination occurred when the reaction 
mixture was aliquoted into each of the four termination mixes. Each of the dideoxy ATP, 
dideoxy CTP, dideoxy GTP and dideoxy T IP  termination mixes contained 0.1 mM of the 
respective dNTP and 1 mM of the remaining three dNTPs. The mixes also contained 0.35 
mM of the respective dideoxy NTP. Termination reactions were incubated at 39°C for 30 
min, after which, the stop solution (10% glycerol, 55% deionized formamide in 2.5X TBE 
(45 mM Tris-borate, 1 mM EDTA) containing 0.5% brom phenol blue and 0.5% xylene 
cyanol was added at a 1:3 dilution.
All sequencing reaction mixtures were heated to 90°C for 3 min prior to loading onto 
the sequencing gel. The radiolabeled DNA was electrophoresed through an 8% 
polyacrylamide/ urea gel (Sambrook, et al., 1989) and the sequence obtained by reading the 
X-ray film after autoradiography.
2.7 Reverse transcription-polymerase chain reaction (RT-PCR)
To compare gene sequences among different SHFV isolates, the genomic RNAs of 
the prototype (LVR), 1-621, Ph0080 isolates of SHFV, which were passage once in rhesus 
monkey macrophages, were purified as described above. The RNA pellets were solubilized 
in DEPC-treated water and annealed to 20 pg of an antisense nucleotide primer by heating
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to 90°C for 2 min, 60°C for 2 min, and the solution was then slowly cooled to room 
temperature in RT buffer (supplied with reverse transcriptase). The antisense primer was a 
synthetic 24-mer, 5 '-TAAAAAGGCTATTACTGCAGGAGC-3', complementary to the 3’ 
flanking sequence of ORF 7 from the LVR isolate of SHFV. RNasin (40 U), 3 /xg BSA, 10 
mM of each of the dNTPs, and 12 U reverse transcriptase (Pharmacia Biotech Inc.) was 
added to the annealed mixture and incubated at 42 °C for 1 hr. The resulting specific cDNA 
were then made double-stranded and amplified by the polymerase chain reaction (PCR). 
Briefly, 4 to 6 fA of the cDNA reaction mixture was added to 20 pg of the antisense primer, 
20 pg of the sense primer, 2 mM of each of the four dNTPs, 4 U Taq polymerase (Perkin- 
Elmer Corp., Branchburg, NJ) and PCR buffer (supplied with Taq polymerase). The sense 
primer, 5'-ATGTACTTATGTTAGGGAGATCG-3, was a synthetic oligomer identical to 
the first 23 nt of ORF 7 within the genome of the LVR isolate of SHFV. The ORF 7 gene 
was amplified for 30 cycles in a thermocycler (Ericomp, San Diego, CA) in which each cycle 
consisted of denaturing the DNA at 94°C for 1 min, annealing the primers to the DNA 
template at 56°C for 30 sec, and primer extension at 72°C for 1 min. During the last cycle, 
the extension step was prolonged for 7 min.
The resulting amplified SHFV ORF 7 genes were sized on 1% agarose gels, purified 
using the Prep-A-Gene DNA Purification System Kit (Bio-Rad Laboratories), and inserted 
into the pCR™ 2.1 plasmid vector using the TA cloning kit (Invitrogen Corp., San Diego, 
CA). The plasmid DNA was amplified in K coli strain TOP 10F (Invitrogen Corp.) and 
screened for inactivation of p-galactosidase gene expression. Minipreps of the plasmid DNA 
from selected clones were made using the Quantum Prep Plasmid Miniprep K it The ORF 
7 cDNAs made from each of the three SHFV isolates were sequenced as described above.
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For SHFV junction sequence identification, the intracellular viral sgRNA were 
isolated as described above. The SHFV sgRNA junction sequences were reverse transcribed 
from the intracellular RNA using cDNA antisense primers complementary to specific SHFV 
genomic ORF sequences. These primer sequences are described later in the next Chapter 
(Results, Table 3). The resulting SHFV cDNA was amplified in a thermocycler as described 
above. The sense primer sequence, 5 '-TAGCCCGGATTGGATAAG-3was identical to 
nucleotides 60 through 77 of the SHFV 5' leader sequence (Zeng, et al., 1995).
2.8 In vitro expression of the SHFV ORF 7 gene
The ORF 7 cDNA clones were prepared as described above. Clones were linearized 
by digestion with the restriction endonuclease Hind ID, extracted with phenohchloroform, 
and ethanol precipitated. The cDNA samples were washed in 70% ethanol and resuspended 
in water at a concentration of 1 Mg/ Ml- In vitro transcription using the Riboprobe System-T7 
was performed as directed by the manufacturer and as described above making both capped 
and uncapped mRNA. The capped mRNA was synthesized by addition of 0.5 mM 
m7G(5,)ppp(5,)G (Ambion, Inc., Austin, TX) to the transcription mixture. After the DNA 
template was digested with RNase-free DNase, the transcripts were extracted with 
phenohchloroform and ethanol precipitated. The precipitated RNA was washed with 70% 
ethanol, dried, and resuspended in water at a concentration of 1 Mgf Ml- The transcribed RNA 
was denatured with 6 M glyoxal (Sigma Chemical Co.) (Sambrook, et al., 1989), 
electrophoresed through a 1% agarose gel, and sized by comparing its electrophoretic 
mobility with those of RNA standards of specified lengths (Bethesda Research Laboratories 
(BRL), Bethesda, MD).
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The transcribed RNA was translated in vitro using the Flexi rabbit reticulocyte lysate 
system, the wheat germ extract system, and the rabbit reticulocyte lysate system as described 
by the manufacturer (Promega Corp.). The products were analyzed for the amount of [3sS] 
cysteine (cpm) incorporated into the protein product by TCA precipitation. Mock reactions 
which lacked RNA template was used as control reactions.
Glycosylalion of the ORF 7 product was performed by the addition of 1 y\ of canine 
pancreatic microsomal membranes to the translation mixtures as directed by the 
manufacturer (Boehringer Mannheim Corp., Indianapolis, IN). The glycosylated ORF 7 
translation product was deglycosylated by treatment with 0.2 U of the endoglycosidase Endo 
F (Boehringer Mannheim Corp.) at 37°C overnight (Winkler, et al., 1987). An additional 
0.1 U of the enzyme was added after 4 hr of incubation in order to obtain complete 
deglycosylation of the glycoprotein. Deglycosylation of SHFV glycoproteins from intact 
virion particles were performed using this same method.
2.9 Production of anti-SHFV sera in African green monkeys
SHFV was obtained from infected MA104 cell cultures and the viral protein 
concentration was determined by using Micro BCA kit (Pierce, Rockford, IL). Two African 
green monkeys were injected intramuscularly (i.m.) with alum-precipitated virus proteins. 
The monkeys were boosted at four week intervals and their sera was titered for anti-SHFV 
activity by ELISA. Immunization was continued until high anti-SHFV antibody titers were 
obtained, after which, blood was collected at six week intervals. Sera was separated from the 
blood by centrifuge at 3000 rpm for 15 min. The sera was frozen at -70 °C for further use.
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2.10 Immunoprecipitation
Immimoprecipitation of radiolabeled SHFV proteins from lysates of infected cells or 
from the in vitro translation products were preformed using standard methods (Sambrook, 
et al., 1989). African green monkey anti-SHFV sera was diluted ten-fold in lysis buffer 
containing the protein sample to be immunoprecipitated and incubated for 4 hr. Meanwhile, 
rabbit anti-monkey IgG (Jackson ImmunoResearch Laboratories, Inc, West Grove, PA) was 
bound to protein A sepharose (Sigma Chemical Co.) for 4 hr in lysis buffer containing 1 % 
BSA. The rabbit anti-monkey IgG-sepharose was added to the anti-SHFV-protein mixture 
and incubated for an addition 4 hr. The mixture was then centrifuged at 3000 rpm for I min. 
The pellets were washed five times with lysis buffer and analyzed by SDS-PAGE. All of the 
incubation steps in this procedure were carried out at 4°C.
2.11 Genetic immunizations
The cloned ORF 7 gene of SHFV was excised from the pCR™ 2.1 plasmid vector 
using the restriction enzymes Hind III and Xho I and inserted into the pcDNA3.1/Zeo(-) 
vector (Invitrogen Corp.) using these restriction sites. After amplification in E. coli., the 
plasmid was purified by equilibrium centrifugation in CsCl-ethidium bromide gradients 
(Sambrook, et al., 1989) and sequenced to substantiate the correct orientation and sequence. 
The concentration of the plasmid DNA was determined by absorbency using a 
spectrophotometer at a wavelength of260 nm. DNA (50 jig) was injected iun. into BALB/c 
mice on weeks 0,2 ,4 , and 10. Blood was obtained from these mice through the retro-orbital 
sinus at week 11. Sera was separated from the blood by centrifugation and assayed by 
ELISA for the presence of anti-ORF 7 antibodies.
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2.12 Monoclonal antibody (mAb) production
In the beginning of this project, mice were immunized to SHFV proteins by Dr. M. 
Philpott (School of Veterinary Medicine, Louisiana State University). Briefly, B ALB/c mice 
were injected with 100 ng of MA104 cell lysate by the intraperitoneal (i.p.) route. The mice 
were injected with cyclophosphosphamide seven days later at a dose of 40 mg/kg body 
weight to eliminate activated B-cells to the MAI04 cell antigens. One week later, 100 /zg 
of purified SHFV was injected i.p. into the mice, followed by an additional three booster 
immunizations at two week intervals. Prior to boosting, sera was collected from the mice 
and assayed for anti-SHFV activity by ELISA. Alternatively, mice were genetically 
immunized with the SHFV ORF 7 gene as described above.
Hybridoma cells were made from the splenic lymphocytes from the immunized 
BALB/c mice. Three days after the final booster immunization, the mice were euthanized 
and their spleens were removed. Splenic lymphocytes were released, washed, and 
resuspended in RPMI 1640. Red blood cells were removed by treatment with 0.83% NH4C1 
for 2 min. After which, the cell suspension was centrifuged at 300 X  G for 10 min at room 
temperature. Meanwhile, myeloma cells (X 63) were harvested and treated with NH4CI 
similarly. The splenic and myeloma cells were counted, mixed at a ratio of 4:1, and 
centrifuged at 300 X G for 5 min. The cell pellets were then treated with 50% PEG and, after 
1 min, RPMI 1640 was added to the cell mixture and the cells were pelleted. The cell pellets 
were resuspended in RPMI 1640 containing 20% FCS and distributed into 96 well plates 
(Costar Corp.). After a 24 hr incubation, RPMI 1640 medium containing hypoxanthine- 
aminopterin-thymidine (HAT; Sigma Chemical Co.) and 20% FCS was added to each well. 
Half of the supernatant was removed from each well and replaced with the fresh HAT
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medium daily for three days, after which, the medium was replaced every 3 to 5 days. The 
hybridoma cells were maintained  in HAT medium for a minimum of 3-4 weeks.
Supernatant fluid from each well positive for growth was screened for anti-SHFV 
activity by ELISA after 14 days. All wells which exhibited anti-SHFV activity were 
transferred to 24 well plates (Costar Corp.). Upon confluency, supernatant fluids from the 
cell cultures were retested by ELISA. Cells which remained positive for anti-SHFV activity 
were split and stored in liquid N2 (-196°C) until needed.
Hybridoma cells were cloned by the limiting dilution method. Briefly, hybridomas 
were plated into 96 well plates at 10, 1, and 0.1 cells/well in the presence of peritoneal 
exudate cells removed from normal, healthy, adult BALB/c mice. These cells were used at 
a concentration o f200 cells/ well.
After seven days at 37°C in a 5% C02, humidified environment, all wells were 
examined by light microscopy. Wells which contained single, actively growing cell clones 
were marked and fed with fresh complete RPMI-1640 medium containing 20% FCS. At 14 
days, the clones were tested by ELISA and positive clones were transferred into 24 well 
plates. The supernatant from the 24 wells plates were further tested for anti-SHFV antibodies 
by ELISA. Positive clones were frozen as soon as possible.
Ascites fluids from mice were used to produce the mAbs as follows. Six to ten week 
old BALB/c mice were injected with 0.5 ml incomplete Freund’s adjuvant i.p. (Sigma 
Chemical Co.). Seven to ten days later, 106 hybridoma cells were injected into these mice i.p. 
Ascitic fluid was harvested within two weeks and mice were “tapped” every other day 
thereafter until abdominal tumors necessitated their euthanasia. Ascites fluids were 
centrifuged to remove cells and were tested for anti-SHFV antibodies by ELISA. Ascites
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fluids containing the antibodies from the same hybridoma were pooled, divided into aliquots, 
and stored frozen at -70 °C
mAb iso types were determined by the ImmunoPureR Monoclonal Antibody Isotyping 
Kit II using the antigen-independent technique according to the manufacturers instructions 
(Pierce Chemical Co.).
2.13 Enzyme-linked immunosorbant assay (ELISA)
Microtiter plates (Costar Corp.) were coated with 0.2- 0.4 ug/ well of SHF viral 
antigens in a carbonate buffer (0.1 mM Na^Oj and NaHCOj, pH 9.6) for 4 hr at room 
temperature. Then, nonspecific binding sites were blocked with 3% fish gelatin (Sigma 
Chemical Co.) in carbonate buffer. The antigen-coated wells were incubated with dilutions 
of various samples to be tested for 30 min at room temperature. After washing 5 times with 
washing buffer (NET; 0.15 M NaCI, 1 mM EDTA, 0.05 M Tris (pH 7.4), and 0.05% Tween 
20), the antigen-antibody complex was then incubated with horseradish peroxidase-labeled, 
species-specific anti-IgG antibodies (Jackson ImmunResearch Laboratories, Inc.) for 30 min 
at room temperature. The wells were washed an additional 5 times and then incubated with 
substrate, 3,3',5,5 '-tetramethy 1 benzidine dichloride as directed by the manufacturer (TMB, 
Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) for 15 min. After the color 
change was observed, the reaction was stopped with 0.1 M H2S04 and the results were read 
on an ELISA reader (Dynatech Lab., Chantilly, VA) at 450 nm.
2.14 Western blot analysis
SHFV proteins were separated by SDS-PAGE (Laemmli, 1970) and 
electrophoretically transferred to polyvinylidine difluoride (PVDF) membranes (Bio-Rad 
Laboratories, Inc.). The nonspecific binding sites on the membrane were blocked with
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blocking buffer (NET containing 10% nonfat dry milk) overnight at room temperature. The 
blots were then washed five time with washing buffer (NET containing 0.05% Tween 20) 
for 5 min each at room temperature, after which, the membranes were incubated with the 
primary antibodies (supernatant fluid from hybridoma cells or diluted anti-SHFV polyclonal 
serum) for 1 hr at room temperature. The membranes were rewashed and horseradish 
peroxidase-conjugated, species-specific, anti- IgG antibodies added to the blots for 1 hr. 
After additional washing with wash buffer, the blots were incubated in the horseradish 
peroxidase substrate, TMB plus enhancer (Kirkegaard & Perry Laboratories, Inc.) for 10 to 
20 min as directed by the manufacturer. The membranes were rinsed in water to stop the 
reaction and then the blots were analyzed visually.
2.15 Competitive binding assays
Direct biotin-labeling of the mAbs was performed using sulfosuccinimidobiotin 
(Immunopure® Sulfo-NHS-Biotin; Pierce) as directed by the manufacturer. After the 
incubation step, all unreacted biotin was removed from the mixture using a 
microconcentrator (cut size 30, 000; Amicon Inc., Beverly, MA) and the biotinylated mAbs 
were stored at 4°C.
Competitive binding assays were performed using a modified ELISA. Briefly, 0.05 
pg of SHFV proteins in carbonate buffer were bound to microtiter plates for 8 hr at room 
temperature. The nonspecific sites were blocked by adding 3% bovine albumin (Sigma 
Chemical Co.) in NET containing 0.05% Tween 20 overnight at room temperature. 
Unlabeled mAbs (Abl) were concentrated from supernatant fluid approximately 2-3 folds 
using a microconcentrator and 100 (A of concentrated Abs were added to the SHFV-coated 
wells and incubated for 1 hr at 37°C. The plates were washed twice with wash buffer and
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the above procedure was repeated for an additional three times in order to block all of the 
specific viral epitopes. Next, the biotinylated mAbs (Ab2) in dilution buffer (NET 
containing 0.5% BSA) were added to the wells and incubated for 1 hr at 37°C. The plates 
were washed 5 times with wash buffer and incubated with horseradish peroxidase-conjugated 
streptavidin (Pierce) in dilution buffer for an additional hour at 37°C. After washing, the 
TMB substrate was added to each well for 15 min. The reaction was stopped by the addition 
of 0.1 M H2S04 and the optical density of each well was determined on the ELISA reader at 
450 nm. The degree to which Abl hindered or blocked the binding of the second antibody, 
Ab2, was determined by the following equation:
% Blocking Ability = 1 - OP Blocked X 100%
OD Unblocked
The ability of each mAb to block its own binding i.e., Abl =Ab2, in this type of assay was 
also measured.
2.16 Animals
All animals used in this study were housed in the vivarium located in the LSU, 
School of Veterinary Medicine. The animals were handled and cared for according to 
methods approved by the LSU Institutional Animal Care and Use Committee.
2.17 Computer analysis
The translation of the SHFV ORFs, the characteristics of the deduced peptides, and 
the hydrophobic pattern according to the method o f Kyte and Doolittle (1982) of specific 
ORFs were determined by the Translation and Protein Analysis programs, respectively,
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supplied in the University ofWisconsin Genetics Computer Group (GCG) software (Program 
Manual for the Wisconsin Package, Version 8).
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3. RESULTS
3.1 Sequence of the 3' end of SHFV RNA genome.
In order to identify the SHFV large envelope glycoprotein gene it was first necessary 
to clone and sequence the entire 3' end of the viral genome which presumably contains the 
ORFs encoding the viral structural protein genes. The first 806 nucleotides from the poly(A) 
tract at the 3 ' end of the SHFV genome were previously reported (Godeny, et al., 1995). 
Beginning with the published sequence, primers were synthesized (Table 1) and the 3 ' end 
of the SHFV genome was cloned and sequenced using a “walk along” method as described 
in Materials and Methods. Because there is no proofreading mechanism during RNA 
transcription, at least three clones were sequenced for each nucleotide in order to obtain the 
majority SHFV genome sequence.
After cloning and sequencing over 40,000 nucleotides, a 6,314 nucleotide sequence 
was obtained representing the entire 3' end of the SHFV genome (Fig. 2). This sequence has 
been deposited with and can be accessed from GenBank using the accession number U63121. 
At the 3’ terminus of this sequence is an 11 nucleotide poly(A) tract followed by the 76 
nucleotide noncoding region, as previously described (Godeny, et al., 1995). The ORF lb 
genes of the arteriviruses contain four conserved domains. The helicase (domain 3) and the 
carboxy-terminal (domain 4) domains are found within the partial ORF at the 5’ end of the 
sequence, suggesting that the first 1,590 nucleotides of this SHFV sequence represents the 
3’ end of the ORF lb  gene.
Between the SHFV ORF lb gene and the 3’ noncoding region, there are nine SHFV 
ORFs which includes three additional ORFs as compared to the other arteriviruses (Fig.3).
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SHF 1293 AAGAACTAAGGTGTGTG 1293
E25-R623 TTCCGTCATTGCTGCTGAG 1541
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Figure 2: The nucleotide sequence of the 3' end of the SHFV genome and its deduced 
amino acid sequence. Position 1 is the 5' end of the nucleotide sequence and position 
6314 is the 3' terminus. The nucleotides encoding the arterivirus conserved ORF lb  
putative helicase (domain 3) and carboxy- terminal (domain 4) domains are underlined 
and double underlined, respectively. sgRNA junction sequences are in bold type and 
double underlined. The ORFs are numbered and the potential N-Iinked glycosylation 
sites are underlined. Termination codons are indicated by an asterisk (*). The location 
of each of the ORFs, the deduced ammo acid sequence, and the potential N-linked 
glycosylation sites were determined from the SHFV genome sequence using the GCG 
Translation program.
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•  •  •  •  •  •
AGTACTACCCCATATCACAGGGACAGAGTTGGTGCAGCGGTCACAATTGACTCCTCTCAA 60
S T T P  Y H R D R V G A A V T  I Q S 3 Q__
•  •  •  •  •  •
GGGTCGACCTACGACGTGGTCACTCTGTACCTGCCTACCAAAGGCAGTCTGACACTGGCT 120
G S T Y  D V V T L  X L P T B £ __ 3 L I  L— ft .
•  •  •  •  •  •
CGTGGTTTAGTAGGAATCACTAGAGCCCGAGAGAGGTTGTATGTTTATGACCCGCATCAT 180  
R G T .  V G I T R A R E R  L Y V Y D P H H
CAGCTCGCAAAGTACTTTAATCTTCAGCCGTCCAGCACCACAATTCGGCCTCATGCTGTA 2 4 0  
Q L A K Y F N L Q P S S T T  I  R P H A V
GTCATCGATGGCAAGGCGCGAGTCATGCTGTCTGACAAGTGCTACGCTGCCCCAGAGGAC 300  
V I  D G K A R V M L S D K C Y A A P E D
TTCCCGGGCATGCTCTGCACTGCGAGGAACGCTACCGCGGCTGACAGGAAGATTTTGGAA 3 6 0  
F P G M L C T A R N A T A A D R K I L E
GAGACTTGCCTCAAATTAGATTTTCTTGAATCTGGCTCACTGTCCCCTCTTCCCCGTGTG 4 2 0  
E T C L K L D F L E S G S L S P L P R V
TGCTATAATCTAGGGTTCTATTACTCACCAGACATTACCAAATTGCTCCCCATTCCATCT 4 8 0  
C Y N L G F Y Y S P D I T K L L P I P S
GAATTGGCAAAACACTGGCCCGTCGCGACTAACCGGAATAATCCAGAGTGGCCCAATCGT 540  
E L A K H W P V A T N R N N P E W P N R
CTAGTGGTTTCAGCCACCCGGCTGTCACCTCTATCACATCCGGCCGTGTGCGCAGGTTAC 600  
L V V S A T R L S  P L S H P A V C A G Y
TACGTGGGGGACTCACTCTTTGTTGGTACTCCAAACGTGACCTCGTACTGGTTGACGAAG 660  
Y V G D S L F V G T P N V T S Y W L T K
TTTCTAGATGGTCGGGCTGTTCCTATGGAAGATTCTGTTTACTCCACTGGCCGGTTTGAA 7 2 0  
F L D G R A V P M E D S V Y  S T G R F E
ATGGATATCAGGGATTATTTGGATTCAGCTGAAAGGGATTTCGCTGCTAAGCACCCACAT 7 8 0  
M D I R D Y L D S A E R D F A A K H P  H
GCTTTCATCGGCGATACGAAGGGCACGACTGTTGGTGGTTGCCATCATATCACCTCACAG 8 4 0  
A F I G D T K G T T V G G C H H I T S O
•  •  •  •  •  •  
TACTTGCCCCATGTGCTACCTGCCGACAGTGTTGTCAAGGTTGGTGTCAGCAAGCCTGGG 900  
Y L P H V L P A D S V V K V G V S K P G
GTCGCTCACAAAGCACTCTGTACGGTAACTGATATCTACCTCCCGATGCTGGGCTCGTAC 960  
V A H K A L C T V T D I Y L P M L G S Y
ACATCACCTCCCACTCAGTCTAAAGTCTACAAAGTAAATGTTGACCACAAGGCGTGCAAA 1 0 2 0  
T S  P P T O S K V Y  K V N V D H K A C K
CTCATGGTCTGGCGTGACCAGACAATGTACTTCCAAGAGGGTTTTGATTATCACACGCTC 1 0 8 0  
L M V W R D O T M Y F O  E G F D Y H T L
(Figure 2, cont’d)
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•  •  •  •  •  •
GTGGATGCACTCCGGTTCGTCCGCTTGAGCAGTGATGGGGTCTATCGCGTCGCCCCTGAC 1 1 4 0  
V D A L R F V R L S S D G V Y R V A P D
GTGACGCCCATGATTGGCAATAGGAGGTTGGACCTGGGCGCTAAACCTCTGAGACCCGTT 1 2 0 0  
V T P M I G N R R L D L G A K P L R P V
GATTTGGCTATCACCCCTTGGGATGACCCCAAATGTGAGTTTCTGGTGACACACGCCTCC 1 2 6 0  
D L A I T P W D D P K C E F L V T H A S
CCATTTGACATGTCTGATGAGTTTCTTCTAGTCAATGCTTTTGATTTCATCAAGGAGGAT 1 3 2 0  
P F D M S D E F L L V N A F D F I K E D
CTGCTAGGCAAATCTGTCACACCTGTGTATTTCTATAAGAGGCTTTCTGAACCCTTGCAT 1 3 8 0  
L L G K S V T P V Y F Y K R L S E P L H
TTTGACCAAAATCTGCCGCCTCATGTTGGAGCTATCCTGTCCAAAGCACCCCGCTTTATA 1 4 4 0  
F D Q N L P P H V G A I L S K A P R F I
TCTCTAGCCAAGGTCTTTAACTTCTGTTTCACACCTACAGCCTGTCACTGTAAGGTGTCA 1 5 0 0  
S L A K V F N F C F T P T A C H C K V S
GTTAAGACCGCCACAGGTGACCACATGTGTAAATGCTCCCTCTCCTCTGATGAGTTTCTG 1 5 6 0  
V K T A T G D H M C K C S  L S S  D E F L
ORF2a M S F C 4
•  •  •  •  •  •
TCCAGGTTTAATCCTACTGTTGGTACTCCTTAAACCAGTCGACTCTTTTGATTTCTTTCA 1 6 2 0  
S R F N P T V G T P *  
P G L I L L L V L L K P V D S F D F F H  24
CTTCTCCTCCTCCTTCAAGTACTATGATCACACCCACATTCATACTGTTTTCAGAGATCT 1 6 8 0  
F S  S S F K Y Y D H T H I  H T V F R D L  44
TATTTCCCATTGCGAAACAAAAATTGCGCCGTGGGCTAAACATCCTCTTGGAATCATTGG 1 7 4 0  
I S H C E T K I A P W A K H P L G I I G  64
GCACAATCAATTTGTATCTGCCTACAACAATTGGGTTCGGCGCGTTTACTCCGTCAACCC 1 8 0 0  
H N Q F V S A Y N N W V R R V Y S V N P  84  
• • • • • •
CATTTATATTGAGGCAGAGAAGGGTTTCAAACATTACTACAGTTACAAGCCCGAGTGCAG 1 8 6 0  
I Y  I E A E K G F K H Y Y  S Y K P E C R  1 0 4
AAGTCAAATTGGCTATCCCGCCACAGTACACGCAGGTACTCGAGAAATCGACTTGCCTAG 1 9 2 0  
S Q  I G Y P A T V H A G T R E I  D L P R  1 2 4
ACTGCTGACTGCACTTAAAACCTATTCAGTGAAGGAACACTCCTTGTGCGTTCGGGCTGC 1 9 8 0  
L L T A L K T Y S V K E H S L C V R A A  1 4 4  
• • • » • • 
CGGATTGCTCGCCCGTCTGCATGAGTTGAGGAAACAAGAGGATTTCAACATCACTGATGA 2 0 4 0  
G L L A R L H E L R K Q E D F  N I T  D D 1 6 4  
•  •  •  •  «  •
TACCTTCACCATCAATTATCACTTGAAGGAGAGTTCTGTACCATGGTTTCAATCTGGTTT 2 1 0 0
ORF2b M V S I  W F 6
T F T I N Y H L K E S S V P W F Q S G F  1 8 4
(Figure 2, cont’d)
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»  •  •  •  •  •
CTACTTGCAGGTCTATCATGCTTCCAGTTTTGCCACGTTTATTGCACCCTTAACTTTACT 2 1 6 0  
L L A G L S C F Q F C H V Y C T L  N F T 2 6
Y L Q V Y H A S S F A T  F I A P L T L L  2 0 4  
• • • • • •
AATAGTTCTTCTGATTCGCAAACCCCGGTTGCTTGCTTTCATCTGCCCAGCGGTAACGTG 2 2 2 0
N S S S D S Q T P V A C F H L P S G  M 46
I V L L I R K P R L L A F I C P A V T C  2 2 4
TCGTTTTCAATCAACCTCACAGCCGTTGTATGTACCCCTAGTTGGAATAAGACCGGGCCC 2 2 8 0  
S. F S I  N L T A V V C T  P S W  N K T G P 66
R F Q S T S Q P L Y V P L V G I R P G P  2 4 4
TTCATTCTCACCTACGGGCGTCTCAGCGCCTCAACGCATGAGTGCACCTCGATTCGTGCG 2 3 4 0  
I  I L T Y G R L S A S T H E C T S I R A  86
S F S P T G V S A P Q R M S A P R F V R  2 6 4
TCTTCCGGTGGGCTCTGGGCAGATCTTAGCATCTGGGAAAGGCCAAGGTCTGTAACTGGC 2 4 0 0  
S S G G L W A D L S I W E R P R S V T G  1 0 6  
L P V G S G Q I L A S G K G Q G L *  2 8 1
ATCTTTAATTTCACTGATCAGCTCGCTGAATCTCATCAGCACGTCTATGCCCTCTTCATA 2 4 6 0  
I  F N F T D Q L A E S H Q H V Y A L F I  1 2 6
GCTGCCTTAACCTTTCACCCTGAACTCTTTGGTCTCAGCCGCAACTACACTCGTTCCCTA 2 5 2 0  
A A L T F H P E L F G L S R  N Y T R S L 1 4 6
ACAATCAAGCAATCATGGAACGAGACAATGATGTGTGTAAACGGCACTGTAGTGTTGACA 2 5 8 0  
T I  K Q S W N E T  M M C V N G T V V L T 1 6 6
ORF 3  M E R D N D V C K R H C S V D K  16  
• • • • • •  
AACGCTACTGCGGCCGAGTACTACATCCGCACGGGGGTAGATTCGCCTATGTACTTTGTG 2 6 4 0  
N A T  A A E Y Y I R T G V D S P M Y F V  1 8 6
R Y C G R V L H P H G G R F A Y V L C G  36  
• • • • » • 
GAATTGTTGCGGCCCTTTCTTCTGTGCCTGCTAATTCTAATGCTGAGCGATGTATGATTT 2 7 0 0  
E L L R P F L L C L L I  L M L S D V *  2 0 4
I V A A L S S V P A N S N A E R C M I C  5 6
GCACCACAAACAACTTCTCTACATTGTTCACTGAATCATCATACCAACATTACCCCCGCT 2 7 6 0  
T T N N F S  T L F T E S S Y Q H Y P R W  7 6
GGCCTGTCTTTCAAGACGGACTCGACTATGTCTATCGTCCACCACTTGTCGCCCAAGTTC 2 8 2 0  
P V F Q D G L D Y V Y R P P L V A Q V L  9 6
TGGGTTATGGCGAAACGTGTGATGATACACAAATCATTGGCACCATAATTGAGACCTATG 2 8 8 0  
G Y G E T C D D T Q I  I G T I I E T Y E  1 1 6
AGACAATTACAGGCAACATGACTGGTATCAAAGAAGCTTTCATTGCTCTTGACTTTGCTG 2 9 4 0  
T I  T G N M T G I K E A F I A L D F A D  1 3 6
ACTGTTTACTCACTGGCATTCTTTACCGGGAACACAACGTGACAGCAGTTTTCCAGCAAC 3 0 0 0  
C L L T G I L Y R E H  N V T A V F Q Q Q 1 5 6
(Figure 2, cont’d)
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AGGATGGCCATATCGTCCTCTGCTGGAACGGGACTGATCCTAGGATTTCTATTAACCAAA 3 0 6 0  
D G H I V L C W  N G T D P R I S I N Q I  1 7 6  
•  •  •  •  •  *
TACCTACTCCTTGGTTCATCTCGCCAGGAGCGCTCAGGTGGGCAACCATCATTTGCGCAT 3 1 2 0  
P T P W F I  S P G A L R W A T I  I C A C  1 9 6  
•  »  •  •  •  •
GCTTGGCGATCTTTAGAGCATTCTATTCTTAATGGGTTCTATACTCACCCACATCACTAC 3 1 8 0  
L A I F R A F Y S *  2 0 5
AGCCTTCCACCATGCTGTCCACGAGCTCCTCGTCTCGTTCTTTGACCTGCTCATCTATAT 3 2 4 0  
ORF 4 M L S T S S S S R S L T C S 5 I W  17 
•  •  •  •  •  •
GGCTGTTATCATTCTTGCTCTGCTGGTTGGTAAAATGCTCTCACTCACAATTAAATCTAT 3 3 0 0  
L L S F L L C W L V K C S H S Q L N L F  37  
• • • •  •  •
TTTCCGCTGTGCCTCAACAGTTGCGCCTACGTCCCGAGGCGCTTACAAAAATGCTTTTGC 3 3 6 0  
S A V P Q Q L R L R P E A L T K M L L R  57
GCCGGTGTCATCAAAGTATCATACCTTACCCTAACCATCCTCTGGGTATCACCACGCATG 3 4 2 0  
R C H Q S  I  I P Y P N H P L G I T T H A  77  
• • • • • •
CGATGGTGAATGCACTGGCGGCCTTTAGTCTTCAGAAGGCAGAAGACCAGGCCCATGCCA 3 4 8 0  
M V N A L A A F S L Q K A E D Q A H A T  97
CCCTTCATGTCAAAGGCATCACTTCAGCTGAGTACACCTACAACGTTTCGTGCGAACCCA 3 5 4 0  
L H V K G I T S A E Y T Y  N V S C E P S  1 1 7
GTTCTTTCACCCTCGACGTGACTGGACTTTCTAAATACCTCACCTCGAAGAATCGAGCGT 3 6 0 0  
S F T L D V T G L S K Y L T S K N R A L  1 3 7  
•  ■ •  •  •  •
TGGAGAGACTTCGCCACTGCGAAGACATCGCACCAATTGTGGGTTACTTGCTCTCAAACA 3 6 6 0
E R L R H C E D I A P I V G Y L L S  M £  1 5 7
•  •  •  •  •  •
GGACGCACAGTTATCTCACTAACCCATGGATGTCCGTGGTCCTCAAGTCACACAGGCCTG 3 7 2 0
ORF 5  M D V R G P Q V T Q A C  12 
X H S Y L T N P W M S V V L K S H R P A  1 7 7
CGGTCGTCTTCTGCTACTATGTTTGCTGTTTCTTACTTGTTCTGCAAATCAAACACATAT 3 7 8 0  
G R L L L L C L L F L T C S A  N O T  H I  32  
V V F C Y Y V C C F L L V L Q I K H I  F 1 9 7  
•  •  •  •  •  •
TTGCTTTCGTAACATACAAACTCAGGTCAAGTTGCACTTCAACACCTCAGTCCTAGCTTG 3 8 4 0  
C F R N  I Q T Q V K L H F  N T S  V L A C 52  
A F V T Y K L R S S C T S T P Q S *  2 1 4
•  •  •  •  •  •
CCTGTACCGTGGCAACGTTGTCATTGACCAAAACATAGAACCGGCCTGCTCAGGCCCCAC 3 9 0 0  
L Y R G N V V I D Q N I E P A C S G P T  7 2  
• • •  •  •  •
GGGTATCCAAACCCGTCAATCTGACAGCGAGGACACAGTGCTACCAACAGCAATTGATTT 3 9 6 0  
G I Q T R Q S D S E D T V L P T A I D L  92  
»  •  «  •  •  *
GGATTTCCTGGCTCTTCTTCTGCACTCACTGAAGTACTTCCCAGTTCTTTTCAACGCCAC 4 0 2 0  
D F L A L L L H S L K  Y F P V L F  N A T  1 1 2
(Figure 2, cont*d)
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TTCTGTCCAGTTTGATAACGAGACATTATGCTACATTGCAAACCTTACTTACTCCTCCAA 4 0 8 0
ORF 6  M L H C K P Y L L L Q  11
S V Q F D N E T  L C Y I  A N L T Y S S ££ 1 3 2
CTCTACATCGTTGCTTGGCACTACTGTGGCTTACTGGGAGACACAGCCGCTGCCAGTTCT 4 1 4 0  
L Y I V A W H Y C G L L G D T A A A S S  31
S 1  S L L G T T V A Y W E T Q P L  P V L  1 5 2
ACTCCTCATACTGTGTCTTCAAATTTGCCTACTACTACCAGCAATCCCCCCCGTGCCGAA 4 2 0 0  
T P H T V S S N L P T T T S N P P R A E  51
L L I L C L Q I C L L L P A I P P V P K  1 7 2
GAATTCGGGGATCAAACTTGCTTGATTTGCCTTCCCCATCCAAATCGCACTTCTTTGACT 4 2 6 0  
E F G D Q T C L I C L P H P  N R T S L T 7 1
N S G I K L A *  1 7 9
TTTGACCTTGCGGAACAAAGTTCGAACACGAGACTATGGTCATCGGGTTGCCTCACAAAT 4 3 2 0  
F D L A E Q S S N T R L W S S G C L T N  91
CTCAAAGGCGGCGTGACAACAACCAGCATCAACGTCACAGTTTCTTCACCTGTCGACCAC 4 3 8 0  
L K G G V T T T S I  N V T V S S P V D H 1 1 1
GTCCTAGCATTGGGACATTGCCTAGCTTTGGCAATCCGATTAGCCGCCCATAACCATAGT 4 4 4 0  
V L A L G H C L A L A I R L A A H N H S  1 3 1
GTGTTCTTCGCCAATCACAGTGATAATCTGTATCTTTGTTATCATGACTCAGGTATATTT 4 5 0 0  
V F F A N H S D N L Y L C Y H D S G I F  1 5 1
•  •  •  •  *  • 
CAGCCTATCACCGCGATCCATCCAGGTGCGTTGCGGTGGGCTTCCATCATAACCTTGTTC 4 5 6 0  
Q P I T A I H P G A L R W A S I  I T L F  1 7 1
ATTGTGATTGCGCGACTCCGCTCCTTAACTACCTAATTATGTACTTATGTTTAGGGAGAT 4 6 2 0  
I V I A R L R S L T T *  1 8 2
ORF 7 M Y L C L G R S  8
CGGAGACTCCGTTGATAGGTTTGTTCCGCACCTCATCTACATCTATCTCATGGTTCTATG 4 6 8 0  
E T P L I G L F R T S S T S I S W F Y V  28  
» • • • • •
TGCTTTTCTTTGTCTCTATTACATTCAGCAGCACCGGCgCATCCGAGAACAACACCGGTA 4 7 4 0  
L F F V S  I T F S S T G A S E  N N T G T 48
•  •  •  •  •  •
CGACCTGGATCAGCATATCAAAGTTTCCGTCATTGCTGCTGAGTCAGATCATAAGCCCTA 4 8 0 0  
T W I S I S K F P S L L L S Q I I S P S  68 
•  •  •  •  •  •
GTTACATTGTAAATATCTCTGTCTGTGGTGCATTTGACATTCAAAATAACACTCACTGGT 4 8 6 0  
Y I  V N T S  V C G A F D I Q  N N T H W F  88
•  •  •  »  •  »
TCACTCCTTGTAATTTGTCTGTCTTGAATCACTCTGACTGTCACACGTGTAAGTCAGAGC 4 9 2 0  
T P C N L S V L N H S D C H T C K S E Q  1 0 8
AGTCAAACCAATCTTTATTATCAAATTGTTCAACGTGTTTCACACACCTTAGTTCTTGTT 4 9 8 0  
S N O S  L L S N C S T C F T H L S S C F  1 2 8
(Figure 2, cont’d)
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•  .  •  • •
TTCTTCACACTTACACTGGACACCACATCAATAACACTAGGCTTCTTTTAGAGACATATT 5 0 4 0  
L H T Y T G H H I  N N T R L L L E T Y L  148 
•  •  •  •  •  •
TAGCAGTCCCCTTACTAACCCATTTATTGAGTTATAAGTTTGCTACAACTGCCTCCTTTC 5 1 0 0  
A V P L L T H L L S Y K F A T T A S F L  168  
• •  •  •  •  •
TTGACTTTGCCTTTTTTGCAGGACTTTCTATTACGGCCTATCGCTATGTTTCACCGGCGA 5 1 6 0  
D F A F F A G L S I T A Y R Y V S  P A I  188  
•  •  •  •  •  *
TATTATTCTTCTTGCCACTCGCTCTCATCTTCTCGGCTATCTTCATCAAGAAGTTAGTGG 5 2 2 0  
L F F L P L A L I  F S A I F I K K L V V  2 0 8  
•  •  •  •  •  *
TAAATTGTATGGCCCTCCGCTTCGCGTGGACTAGGCACACCAATTTCATCATTGACGACC 5 2 8 0  
N C M A L R F A W T R H T N F I  I  D D R  2 2 8  
»  •  •  •  *  *
GAGGTAGATTATTTGTCAACCACGACGACGTGCTGATTTCCGACCCACAGGGACTGCGGG 5 3 4 0  
G R L F V N H D D V L I S D P Q G L R V  2 4 8  
•  •  •  •  •  •
TTGGACCTCATAAGGTCAGAGCCGCTAAGGTAATACTTGGTGGACGGGAGGCAAATTTAC 5 4 0 0  
G P H K V R A A K V I L G G R E A N L L  2 6 8
TCAGACAAGCACACGTCGAAGAGTGGTCATGGTAGTATCCCTTTGCAGTGACCCGGGGTA 5 4 6 0
ORF 8 M V V S L C S D P G Y  11 
R Q A H V E E W S W *  278
.  .  •  •  •  •
CACTACCTTGGCTTTTACTATTGCTCCTGCATTAATAGCCTTTTTAAGATATTTCCGCCC 5 5 2 0  
T T L A F T I A P A L I A F L R Y F R P  31 
« •  »  •  •  •
ATCCGTGCGCGGTTTCATATGCTTGGTATGCATTGCTACACTTGCTTATGCTGCAACTGC 5 5 8 0  
S V R G F I C L V C I A T L A Y A A T A  51 
• • • • • • 
TTTCAATGAACATTCCCTTGCAACATTACTAACAATTGGGTTCAGTCTGGTATACTTGAC 5 6 4 0  
F N E H S L A T L L T I G F S L V Y L T  71
CTATAAATTCATCACGTGGACCATTCTACGTGTGCGGATGTGTTGGCTCGGCCGGCAATA 5 7 0 0  
Y K F I T W T I L R V R M C W L G R Q Y  91 
»  •  •  •  »  •
CATAACCGCCCCTTCCAGTATGGTTGAGTCATCCCTTGGCCGTTTAGCGATTAACGCGAC 5 7 6 0  
I T A P S S M V E S S L G R L A I  N A T  1 1 1
TGGTTCTACCGCAGTCGTAACTCGCCGATCTGGCATGACAGCAGTCAATGGTAGTCTCAT 5 8 2 0  
G S T A V V T R R S G M T A V  N G S L M 131
•  •  •  •  •  *
GCCGGATGTGAAAAGGATCATACTCAATGGAAGGGTTGCCGCCAAAAGGGGTCTTGTTAA 5 8 8 0  
P D V K R I  I L N G R V A A K R G L V N  1 5 1
•  •  •  •  •  *
CCTGAGGAAGTATGGCTGGCAAACCAAAAACAAATAACAAGGGAAAATCCCAGTCCAGAG 5 9 4 0  
L R K Y G W Q T K N K *  162
ORF 9 M A G K P K T N N K G K S Q S R G  17 
• • •  •  •  *
GAGGGAATAGGCTTCCCCAACGACCTCGCCGCAGCACTCAACAACGTAGAGCTGCTCCTG 6 0 0 0  
G N R L P Q R P R R S T Q Q R R A A P V  37
(Figure 2, cont’d)
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•  • • • • •
TCCACAAGCCTCTAAATGAGACACATTATGTTTTCGCCGAACCCGGCGACCTCCGAGTTG 60 6 0  
H K P L M K T  H Y V F A E P G D L R V V  57
TTCTACCTGGTCCCACCTCAGCACACATCAAACAGCTGCTGATCAGGTACTACGACAACG 61 2 0  
L P G P T S A H I K Q L L I R Y Y D N G  77 
•  • • • • •
GAGGCGGAAATCTTTCATATGACGGACAGAGAATCAATTTTGCTGCTATCATCACACCAC 618 0  
G G N L S Y D G Q R I N F A A I I T P P  97 
•  • • • * •
CACACAACATGCTGAAGCAGCTGGCGAAGGTCACCTCCTCCACCTAGGCCAGACACTGAT 62 4 0 
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Figure 3: Schematic representation of the SHFV 3' ORFs as compared to the 3' ORFs 
of the other arteriviruses. AO ORFs are drawn approximately to scale.
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These SHFV ORFs were numbered 2a, 2b, 3, 4, 5, 6, 7, 8 and 9 using conventional 
nomenclature (Cavanagh, et al. 1990). ORFs 2a, 2b, 3 ,4 ,5 ,6 ,7 ,8  and 9 encode peptides of 
281,204,205,214,179,182,278, 162 and 111 amino acids in length, respectively (Fig. 2, 
Table 2). The smallest ORF is ORF 9 which encodes a peptide of approximately 12.3 kDa 
and the largest ORF is ORF 2a which encodes a peptide with a mass of 31.8 kDa. ORF 7 
encodes the second largest peptide of 31.3 kDa. The remaining ORFs encode peptides 
between 17.8 and 24.1 kDa (Table 2). All of the ORFs encode neutral to basic peptides with 
estimated pi values at pH 7.0 between 6.2 and 11.7. With the exceptions of ORFs 4 and 7, 
each of the SHFV 3’ ORFs overlap their adjacent 5' ORFs (Table 2). A unique feature of the 
SHFV genome is that ORF 2a overlaps ORF lb by 41 nucleotides; there is no overlap 
between ORFs lb and the adjacent ORFs 2 in the other arterivirus genomes. Each ORF 
contains at least one potential N-linked glycosylation site (Fig. 2, Table 2). The ORF 2b and 
7 peptides contain the most N-linked glycosylation sites with 10 and 8, respectively. Four 
of the 3' ORFs encode peptides containing only one or two potential N-linked glycosylation 
sites (Table 2).
3.2 Identification of the sgRNAs synthesized daring replication.
Northern blot analysis of RNA extracted from SHFV-infected cells detected six 
polyadenylated virus-specific sgRNAs, with estimated lengths of 4.7, 3.3,2.7,2.0,1.2 and 
0.65 kb (Godeny, et al., 1995; Zeng, et al., 1995). However, since SHFV encodes nine ORFs 
at the 3' end of the genome and the arteriviruses are not known to translate more than one 
ORF from each sgRNA, nine sgRNAs should be produced during SHFV replication. 
Therefore, RT-PCR, which is a more sensitive method than Northern blot analysis, was used 
to identify the number of sgRNAs produced during replication and to map each of the leader-































2 a 5 . 0 4 9 843 41 281 3 1 . 8 10 .2 1 9•
2b 5 . 0 4 9 612 310 204 2 2 . 7 6 . 7 10 9•
3 4 . 0 3 2 615 160 205 2 3 . 1 6 . 2 4 9•
4 3 . 4 5 4 642 - 4 2 214 2 4 . 1 9 . 5 2 9•
5 2 . 8 2 7 537 148 179 1 9 . 1 6 . 2 6 ?
6 2 . 6 4 2 546 175 182 1 9 . 6 7 . 5 4 9•
7 1 . 9 2 1 834 - 5 278 3 1 . 3 8 . 2 8 9•
8 1 . 2 1 0 486 4 162 1 7 . 8 1 1 . 3 2 p20
9 0 . 6 2 9 333 23 111 1 2 . 3 1 1 . 7 2 p l 5
'Number of nucleotides the ORF overlaps the adjacent 5' ORF.
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body junction sites on the sgRNAs. Table 3 shows the reverse primer sequences used for the 
RT-PCR reactions and the location of the primer sequences downstream of the respective 
ORF initiation codons. The forward primer used in the reactions was located within the 
SHFV 5' leader sequence as described in Materials and Methods.
Although SHFV encodes nine ORFs at the 3' end of its genome, only eight SHFV 
sgRNA junction sequences were found (Fig. 4). These were located upstream of ORF 2a and 
of ORFs 3 through 9. ORF2a and 2b appear to share the same junction sequence as the ORF 
2a junction region was obtained when the ORF 2b primers were used. There is a junction 
sequence located upstream of each of the remaining seven SHFV ORFs. The consensus 
junction sequence among the sgRNAs is a nananucleotide sequence, 5’- 
(U/CXC/LONCU/QCU/CXA/C/GjACCC/LO-S’, in which only the residues at position 7 and 
8 are strictly conserved (Fig. 4). The distance between the junction sequence and the 
initiation codon for the respective ORF varies from 1 nt (ORF 5) to 177 nts (ORF 6).
Based on these results, it is assumed that SHFV produces eight sgRNA species during 
replication (Fig. 5). Using conventional nomenclature (Cavanagh et al., 1990), these sgRNAs 
were designated RNAs 2 through 9 with calculated lengths o f 5.049,4.032, 3.454, 2.827, 
2.642,1.921,1.210 and 0.629 kb, respectively. These size estimates exclude the 3’ poly(A) 
tail but include the 208 nt 5' leader sequence. With the exceptions of sgRNAs 3 and 5, these 
RT-PCR-generated sgRNA lengths correspond to the estimated lengths generated by 
Northern blot analysis (Godeny, et al., 1995; Zeng, et al., 1995) as shown in table 4.
33 Enumeration and characterization of the SHFV structural proteins.
It was previously reported that SHFV contains at least four major structural proteins 
with apparent molecular masses of 15 (pi 5), 20 (p20), 38-46 (p42) and 48-60 (p54) kDa, as
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Table 3. Reverse primer sequences used for RT-PCR amplification of the SHFV 
sgRNA junction sequences and the location of the primer sequence 







2 a TTGAAACCCTTCTCTGCC 2 6 3
2b GCAGATGAAAGCAAGCAAC 104
3 TTCGCCATAACCCAGAAC 28 2
4 AAAGAACTGGGTTCGCAC 338
5 GAAGTGCAACTTGACCTGAG 115
6 CGCAATCACAATGAACAAG 50 6
7 AAAGTCAAGAAAGGAGGCAG 490
8 GTCGCGTTAATCGCTAAAC 313
9 CATATGAAAGATTTCCGCC 2 3 1
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Figure 4: Identification of the SHFV sgRNA junction sequences. The sequences of the 
sgRNA junction regions are compared to the SHFV genome sequence. The 5' leader 
sequence, located at the 5' end of the SHFV genome, was determined previously (Zeng, 
et aL, 1995) and is shown on the top line of each comparison. Viral genome sequences 
upstream of each of the SHFV ORFs is shown on the bottom line of each comparison. 
Genomic nucleotides in bold type contribute to the sgRNA sequence. Nucleotides 
which are identical in both the sgRNA and genome sequences are identified with a 
colon. Initiation codons are indicated in bold type and underlined. The overall 
junction region consensus sequence is shown at the bottom of the figure with the most 
common nucleotide represented in the middle line.
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5 ' L e a d e r  5 '
ORF 2a  sgRNA 5 '
Genome 5 '
5 ' L e a d e r  5 '
ORF 3 sgRNA 5 '
Genome 5 '
5 ' L e a d e r  5 '
ORF 4 sgRNA 5 '
Genome 5 '
5 ' L e a d e r  5 '
ORF 5 sgRNA 5 '
Genome 5 '
5 ' L e a d e r  5 '
ORF 6 sgRNA 5 '
Genome 5 '
5 ' L e a d e r  5 '
ORF 7 sgRNA 5 '
Genome 5 '
5 ' L e a d e r  5 '
ORF 8 sgRNA 5 '
Genome 5 '
5 ' L e a d e r  5 '
ORF 9 sgRNA 5 '
Genome 5 '
C o n s e n s u s
.ADDDGCAGACCCPCCPPAACCAPGPPCPGPGAGPGCCCPCG. . . 3 ' 
. APPPGCAGACCCPCCPPAACPPCPGPPPCAC— 7 7 n t -AUG. . . 3 ' 
. COCUAGCCAAGGOCUOUAACUUCUGOOOCAC-' 7 7 n t - £ 2 £ -  ”  3 '
.AOUUGCAGACCCUCCUUAACCAOGUOCUGUGAGUGCCCUCG. . . 3 ' 
•  • » • • » • • • • • • • • • • •  •  •  •  •  •  •  •  •
. AUTOGC^GACCCUCCUOCACCCUGAACUCUO- 4 5 n t - ACJG. . . 3 ' 
. UAGCUGCCUUAACCOUdCACCCUGAACUCTU- ’ 4 5 n t - AUG I "  3 '
. ADOPGCAGACCCOCCPPAACCAPGPPCPGPGAGPGCCCPCG. . . 3 ' 
. APUPGCAgACCc 6c c66a ACCAAAPACCOAC-1 2 4 n t-APG. . . 3 ' 
.AOCCUAGGAOOOCDAdOAACCAAAOACCaAC^iiint-^S- • - 3 '
.ADOOGCAGACCCPCCPPAACCAPGPPCPGPGAGPGCCCPCG. . . 3 ' 
•  • • • • • » • • • • • • •  • • • • •  •  •  •  • • •  •
. AOOPGCAGACCCOCACPAACCCAOGGAUGUCCGOGGOCCUC. . .  3 ' 
. CGCACAGDDADCDCACnAACCCADGGAPGPCCGPGGPCCPC! ! ! 3 '
. ADDUGCAGACCCUCCUDAACCAUGUUCUGUGAGUGCCCUCG. . . 3 ' 
•  • • • • • • • » • • • • • • • •  •  •  •  •  •
. APaPGCAGACCCPCCP6GACCAAAACAaAGA-168nt-APG. . . 3 ' 
. GPGGCARCGPPGPCAPUGACCAAAACADAGA-i68n-t-AUGl I I 3 '
.ADDUGCAGACCCPCCPPAACCAPGPPCPGPGAGPGCCCPCG. . . 3 ' 
. Ao ppg c a g a c c c pcc ppaAc p Ac c pa a ppa u g pa c ppa pg p  . . . 3 ' 
. g cg cg a cpccgcpccppa a c6 acc6 aad6 apg6 a c p p a p g p I 11 3 '
. APPPGCAGACCCPCCPPAACCAPGUUCPGUGAGUGCCCUCG. . . 3 ' 
• • • • • • • • • • • « • • • •  •  •  •  •  •  •
. APPPGCAGACCCPCCPCAACCACGACGACGP—117 n t  - fiJ2£ • • • 3 ' 
.GAGGPAGAPPAPPPGPCAACCACGACGACGP-ii7nt-ifflSl ! I 3 '
. APUOGCAGACCCPCCPPAACCAPGPPCPGPGAGPGCCCPCG. . . 3 ' 
. APPPGCAGACCCPCCPPAACCPGAGGAAGPAPGGCPGGCAA. . . 3 ' 
. CCAAAAGGGGPCPPGPPAACCPGAGGAAGDAPGGCPGGCAA.I I I 3 '
C P  CC C P  
5 ' -U C N U U A A CC- 3 ' 
G
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Figure 5: Schematic representation of the SHFV sgRNAs produced during virus
replication. The deduced sgRNAs and die ORFs translated from each RNA species are 
shown. ORFs are indicated by gray boxes and die 5' leader sequences are depicted by 
white boxes. Solid lines represent untranslated RNA. The lengths of the sgRNAs are 
shown to the right of each RNA. ORFs and RNAs are drawn approximately to scale.
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2a 843 5.049 4.7
2b 612 5.049 4.7
3 615 4.032 ?
4 642 3.454 3.3
5 537 2.827 ?
6 546 2.642 2.7
7 834 1.921 2.0
8 486 1.210 1.2
9 333 0.629 0.65
“Results from Godeny, et al. (1995) and Zeng et al. (1995)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
59
measured by SDS-PAGE analysis (Godeny and Brinton, 1992; Godeny, et al., 1995). 
Because the p42 and p54 glycoprotein bands migrate as very broad bands by polyacrylamide 
gel electrophoresis, the exact number of glycoproteins in the SHFV virion particle has not 
been fully determined. Therefore, attempts were made to determine the number of individual 
viral glycoproteins within the p42 and p54 bands.
Metabolically-radiolabeled SHFV particles were treated with endoglycosidase F, 
which cleaves both the asparagine-linked high-mannose and complex glycans from the 
glycoprotein peptide backbone (Winkler, et al., 1987). The resulting SHFV peptides were 
then separated by SDS-PAGE. As shown in figure 6, lane A, four major structural proteins 
are observed with untreated SHFV particles, p i5, p20, p42 and p54. No peptides were 
detected in mock-infected cell samples (lane B). Interestingly, treatment of the SHF viral 
particles with endoglycosidase F resulted in the disappearance of the p42 and p54 bands and 
the emergence of four new bands with molecular masses between 28 and 30 kDa (Fig. 6, lane 
C). Two additional bands appeared at 16 and 22 kDa (lane C); however, these may be the 
digestion products of the peptides which migrate at 27 and 33 kDa (lane A). These peptides 
are occasionally observed in SDS-PAGE-separated SHFV samples but have not been 
determined to be viral in origin (Godeny, et al., 1995).
Further, Western blot analysis using anti-SHFV polyclonal antisera made in African 
green monkeys support the radiolabeled protein data. As shown in figure 7, pl5, p20, p42 
and p54 were all detected from intact SHFV particles by Western analysis (lane A). 
Treatment of the virus with endoglycosidase F resulted in the detection of the four new 
peptides, between 28 and 30 kDa and the lack of p42 and p54 detection with the anti-SHFV 
serum (lane B). Taken together, the radiolabeled virus data and the Western analysis data
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Figure 6: Autoradiograph of l4C-amino acid-labeled SHFV structural proteins.
Proteins from purified, extracellular SHFV particles (lane A), media obtained from 
mock-infected MA104 cells (lane B), and endoglycosidase F-treated, purified, 
extracellular SHFV particles (lane Q  were separated by SDS-PAGE. Lines with 
numbers indicate the positions and molecular mass (kilodaltons) of standard proteins, 
arrows indicate the SHFV structural proteins, and dots represent unique peptides 
obtained after endoglycosidase F treatment.
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Figure 7: Western blot analysis of SHFV structural proteins treated (lane B) or
untreated (lane A) with endoglycosidase F. Viral proteins were separated by SDS- 
PAGE. African green monkey anti-SHFV sera was used as the primary antibody for 
the Western analysis. Lines with numbers at the left of die figure indicate the positions 
and molecular mass (kilodaltons) of standard proteins; whereas lines on the right 
indicate the SHFV structural proteins. Arrows represent unique peptides obtained 
after endoglycosidase F treatment.
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suggest that the SHFV p54 and p42 glycoprotein bands represent at least four viral 
glycoproteins.
It had been shown that the capsid protein of EAV was phosphorylated (Zeegers, et 
al., 1976). Therefore, attempts were made to determine if  the SHFV capsid protein was a 
phosphoprotein. Both EAV and SHFV particles were metabolically-radiolabeled with 32P- 
phosphate, separated by SDS-PAGE, and detected by autoradiography. A phosphoprotein 
band was detected with a molecular mass of approximately 14 kDa (capsid protein) in the 
EAV sample but no phosphorylation was detected in the SHFV preparation.
Further post-translational modification studies were performed. Many viral proteins 
have been shown to be myristylated (reviewed in Towler, et al., 1988). Therefore, SHFV 
particles were metabolically radiolabeled with 3H-myristic acid to determine if any of the 
SHFV structural proteins were myristylated. Although we could not detect myristylation of 
any of the SHFV structural proteins, a peptide with an approximate molecular mass of 6 kDa 
(Vp4; Chow, et al., 1987) was myristylated in the coxsackievirus B3 control sample. 
Together, these data suggest that the SHFV structural proteins are neither phosphorylated nor 
myristylated.
3.4 Characteristics and identity of the SHFV ORF 7 gene product.
Since the SHFV ORFs 8 and 9 were identified as the capsid and membrane protein 
genes, respectively, it was of interest to map one of the large envelope glycoprotein genes 
on the SHFV genome. It was previously shown that the large envelope glycoprotein genes 
of EAV, LDV and PRRSV were mapped to ORF 5 on the respective genomes (de Vries, et 
al., 1992; Faaberg and Plagemann, 1995; Meulenberg, et al., 1995). Since ORF 5 of these 
viruses is the third ORF from the 3 ' end of the genome, the corresponding ORF in SHFV,
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ORF 7, was examined to determine if it also encoded one of the SHFV large envelope 
glycoproteins. It should be noted that the SHFV ORF 7 gene encodes a peptide with eight 
potential N-linked glycosylation sites (Table 2).
A hydrophobicity plot was performed on the peptide encoded by the SHFV ORF 7 
gene using the method of Kyte and Doolittle (1982). As shown in figure 8, there is a 
hydrophobic region toward the middle of this peptide spanning amino acids 140 through 204. 
Three peak hydrophobic domains are observed within this region. The carboxy terminal end 
of this peptide shows hydrophobic domains interspaced with hydrophilic regions; whereas, 
the amino terminus is more hydrophilic than hydrophobic (Fig. 8).
The SHFV ORF 7 hydrophobicity plot is similar to plots generated for the ORF 5 
products of EAV, LDV, and both the American and European isolates of PRRSV (Fig. 8): 
all five peptides contain a hydrophobic region toward the center of the sequence; the carboxy 
terminus contains both hydrophilic and hydrophobic regions; and the amino terminal ends 
of the peptides are more hydrophilic than hydrophobic. Further, computer analysis of the 
SHFV ORF 7 peptide sequence and the amino acid sequences of the ORF 5 products of LDV 
and PRRSV/LV using the GAP program within the GCG software package shows 53% and 
57% sequence similarity, respectively. These data suggest that the peptide encoded by the 
SHFV ORF 7 may be similar to the products of the ORF 5 genes of the other arteriviruses.
To further identify the SHFV ORF 7 gene product, the gene was cloned and 
expressed. The ORF 7 gene was amplified by RT-PCR and the amplified product was 
separated by electrophoresis through an agarose gel as described in Materials and Methods. 
As shown in figure 9, a polynucleotide product of approximately 950 nucleotides was 
obtained by these methods. After cloning and sequencing this ORF 7 product, it was
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Figure 8: Hydrophobicity plot for the SHFV ORF 7 peptide as compared to the
hydrophobicity plots of the EAV, LDV, and PRRSV ORF 5 peptides. PRRSV/LV and 
PRRSV/VR-2332 are the European and American PRRS viruses, respectively. 
Hydrophobicity was determined as described by Kyte and Doolittle (1982) using the 
GCG PeptideStructure program.
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Figure 9: Ethidium bromide staining of the SHFV ORF 7 RT-PCR product after 
electrophoresis through a 1% agarose geL Lane + indicates that SHFV genomic RNA 
was added to the RT-PCR reaction, while lane - indicates that the RT-PCR reaction 
was performed without the viral RNA. The lines and numbers refer to the positions of 
standard DNAs and their lengths (kilo bases).
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determined that the amplified product was 870 nucleotides in length and contained the 
identical ORF 7 sequence as shown in figure 2.
In order to express the ORF 7 product in-vitro, it was first necessary to transcribe 
RNA from the cloned ORF 7 gene. Sequencing showed that the ORF 7 gene was oriented 
within the pCR plasmid vector under the control of the T7 promoter. Therefore, ORF 7 RNA 
was transcribed using T7 polymerase as described in Materials and Methods. Because the 
amount of translation product derived from capped and uncapped mRNAs can differ 
depending on the gene being expressed, both capped and uncapped ORF 7 RNAs were 
transcribed (Fig. 10). The uncapped RNA migrated as a polynucleotide approximately 900 
nucleotides in length (lane A) while the capped RNA migrated a little slower (lane C). No 
RNA was transcribed in the control reactions (lanes B and D). It also appeared that the 
uncapped RNA was transcribed at a slightly higher concentration than the capped RNA.
The transcribed ORF 7 mRNA was next used as template for in-vitro translation of 
the ORF 7 product For the remainder of this study only the uncapped transcription product 
was used because no difference was observed in the amount of product translated from the 
capped or uncapped mRNA. Both the rabbit reticulocyte lysate and wheat germ extract 
systems were used for the in-vitro translation of the ORF 7 product As shown in figure 11, 
a single protein product with a molecular mass of about 31 kDa was observed using the 
wheat germ extract system (lane B). This mass corresponds to the predicted coding capacity 
of the SHFV ORF 7 gene. No product was translated using the wheat germ extract system 
without mRNA added (lane A) or the rabbit reticulocyte lysate system with (lane D) or 
without (lane C) ORF 7 mRNA. Although this experiment showed that the SHF ORF 7 gene 
could be expressed in-vitro, the results were disappointing. Since the next step in
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Figure 10: Ethidium bromide-stained, agarose gel-separated, in vitro transcription 
products of the SHFV ORF 7 cDNA. The uncapped mRNA product is seen in lane A; 
whereas the capped mRNA product is shown in lane C. As negative controls, the ORF 
7 cDNA was removed from the uncapped and capped reactions, lanes B and D 
respectively. The lines and numbers indicate the positions of standard RNA markers 
and their lengths (kilobases).
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Figure 11: Autoradiographic comparison of the wheat germ extract and rabbit
reticulocyte lysate systems for the in vitro translation of the SHFV ORF 7. Products 
from the wheat germ extract reactions are shown in lanes A and B, and lanes C and D 
contain the products from the rabbit reticulocyte lysate reactions. ORF 7 mRNA was 
removed from the reactions to serve as negative controls (lanes A and C). Lines and 
numbers indicate the position and molecular mass (kilodaltons) of protein standards.
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showing that this ORF encodes a viral glycoprotein was to express the product as a 
glycoprotein and the rabbit reticulocyte lysate system is the only in-vitro glycoprotein 
expression system available, it was necessary to express the peptide in the rabbit system. 
Because the protein product was made using the wheat germ extract system, it was possible 
that the ion concentrations in the rabbit reticulocyte lysate kit were not optimal. Therefore, 
the ORF 7 mRNA was next expressed using the Flexi rabbit reticulocyte lysate kit which 
allows for the optimization of ion concentrations. It was found that the elimination of Mg4-" 
and altering the KC1 concentration in the rabbit reticulocyte lysate reaction resulted in the 
production of the ORF 731 kDa peptide (Fig. 12, lane A). Optimal KC1 concentration in the 
reaction was determined to be 3.0 mM.
Canine pancreatic microsomal membranes were added to the Flexi rabbit reticulocyte 
reaction mixture in order to determine if the SHFV ORF 7 product was a glycoprotein. 
Addition of these microsomal membranes shifted the molecular weight of the ORF 7 product 
from 31,000 to approximately 52,000 (Fig. 12, lane B), suggesting that ORF 7 encodes a 
viral glycoprotein. This molecular weight range coincides with the SHFV p54 glycoprotein. 
Similar to pS4, the 52 kDa glycoprotein also migrated on SDS-PAGE as a wide band.
To confirm that the 52 kDa ORF 7 product was a glycoprotein, the in vitro translation 
product was treated with endoglycosidase F to remove the carbohydrate residues. As 
expected, this treatment had no effect on the size of the ORF 7 product synthesized in the 
absence of microsomal membranes. In contrast, endoglycosidase F treatment of the 52 kDa 
glycoprotein resulted in a shift in the molecular weight of the peptide to approximately 
29,000 (Fig. 12, lane C). Surprisingly, this molecular weight is smaller than the ORF 7 
product synthesized in the absence of microsomal membranes (31,000), suggesting that a
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Figure 12: Autoradiograph of SDS-PAGE-separated, in vitro translation products of 
the SHFV ORF 7 gene using the Flexi rabbit reticulocyte lysate system. The in vitro 
translation reactions were performed with (lanes B and C) or without (lane A) the 
addition of canine pancreatic microsomal membranes. Lane C shows the glycosylated 
ORF 7 product after digestion with endoglycosidase F. Lines and numbers indicate 
positions and molecular masses (kilodaltons) of protein standards. Arrows point to the 
ORF 7 products.




Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
78
signal sequence of approximately 2 kDa was cleaved from the peptide during glycoprotein 
synthesis. It is noteworthy that the 52 kDa ORF 7 product and its cleavage product, 29 kDa, 
correspond to the SHFV p54 and one of its potential cleavage products, 28-30 kDa (Fig. 7), 
suggesting that ORF 7 may encode one of the p54 glycoproteins.
In order to determine the identity of the SHFV ORF 7 product, anti-SHFV sera was 
needed. Therefore, two antisera directed against SHFV proteins were produced: polyclonal 
monkey antiserum against whole virus particles and monospecific mouse antiserum against 
the ORF 7 product
Polyclonal anti-SHFV serum was made in African green monkeys using gradient 
purified whole virus as described in Materials and Methods. Serum was obtained from the 
monkeys and a dilution curve using ELISA with whole virus particle proteins as antigen was 
determined (Fig. 13). Using a 50% reduction in the maximum O.D. obtained by ELISA as 
endpoint the antisera exhibited an ELISA titer of 5,000. Normal African green monkey 
serum did not specifically react to. the SHFV antigens. As expected, this antisera reacted to 
all of the known SHFV structural proteins (Fig. 7).
Monospecific, polyclonal anti-SHFV ORF 7 product serum was made in mice. As 
described in Materials and Methods, the ORF 7 gene was removed from the pCR 2.1 vector 
and placed under the cytomegalovirus promoter within the pcDNA 3.1 plasmid vector. The 
pcDNA-ORF 7 plasmid was used for genetic immunizations of BALB/c mice. Serum was 
obtained from these mice and assayed by ELISA using proteins from gradient-purified SHFV 
as antigen. The dilution curve of the murine serum is shown in figure 14. The anti-ORF 7 
serum exhibited a titer o f800 when assayed against the SHF virus particle proteins; normal 
B ALB/c mouse sera did not specifically react with these antigens. Since the anti-ORF 7
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Figure 13: Dilution curve of polyclonal African green monkey anti-SHFV sera as 
assessed by ELISA using viral structural proteins as antigen. The solid curve 
represents the anti-SHFV sera while the dotted curve represents normal monkey sera. 
All dilutions were performed in triplicate. Dots depict the mean value for each dilution 
and the standard deviation is shown.
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Figure 14: Dilution curve of monospecific murine anti-SHFV ORF 7 sera as assessed 
by ELISA using viral structural proteins as antigen. The solid curve represents the 
anti-ORF 7 sera while the dotted curve represents normal murine sera. All dilutions 
were performed in triplicate. Dots depict the mean value for each dilution and the 
standard deviation is shown.
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serum reacted to proteins from purified SHFV particles, the ORF 7 product must be a viral 
structural protein.
To further investigate whether the ORF 7 gene encodes one of the SHFV p54 
glycoproteins, immunoprecipitation studies were performed using the monospecific murine 
anti-SHFV ORF 7 serum. When intact SHFV particles where used as antigen, all of the 
known SHFV structural proteins were immunoprecipitated out of the mixture (Fig. 15, lane 
A), suggesting that the ORF 7 product is found on the outer surface of the viral envelope. 
As expected, this antisera also immunoprecipitated both the nonglycosylated and 
glycosylated forms o f the in-vitro expressed ORF 7 product (lanes C and D, respectively). 
This antisera did not react with proteins from mock-infected cell supernatants (lane B) nor 
the in-vitro translation reaction mixture without mRNA (lane E). Note that the glycosylated 
form of the ORF 7 product migrates with the SHFV p54 protein band (Fig. 15, lanes A and 
D).
Thus far, the data suggests that the ORF 7 gene encodes one o f the large envelope 
glycoproteins, p54, of SHFV. To determine if  anti-SHFV sera from other monkey species 
could recognize the ORF 7 product, antisera from naturally infected patas and rhesus 
monkeys were obtained from P. Jahrling (USAMRIID). Reactivity of this sera with SHFV 
proteins and ORF 7 products were determined by ELISA and is reported in Table 5. All of 
the monkey anti-SHFV sera reacted against SHFV proteins and both the glycosylated and 
nonglycosylated forms of the ORF 7 product; however, they did not react to proteins from 
mock-infected cell extracts nor to rabbit reticulocyte lysate proteins. As expected, the 
monospecific murine serum reacted to the same antigens as the monkey antisera (Table 5).
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Figure 15: Autoradiograph of immunoprecipitated, SDS-PAGE-separated samples 
using monospecific murine anti-SHFV ORF 7 sera. This antisera was used to 
immunoprecipitate intact SHFV particles (lane A), proteins from mock-infected MAI 04 
cell supernatants (lane B), in vitro expressed ORF 7 products made in the presence 
(laneD) and absence (lane C) of microsomal membranes, and proteins from them vitro 
translation reaction without the addition of SHFV RNA (lane E). Lines and numbers 
indicate the positions and molecular masses of protein standards (kilodaltons).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.























Table S. ELISA values* using anti-SHFV serab from various monkey species or from genetically- immunized mice* against 
native SHFV proteins or in vitro expressed ORF 7 products
Anti-SHFV Normal Anti-SHFV Anti-SHFV Anti-ORF 7 Normal 
African green African green patas rhesus murine murine








































“ELISA values are expressed as O.D.4S0.
bAU monkey sera was diluted 1:5000 and all murine sera was diluted 1:800. 
cMice were genetically-immunized with the SHFV ORF 7 gene.
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Since antibodies directed against the large envelope glycoproteins of the other 
arteriviruses can neutralize the respective viruses, it is expected that if the ORF 7 gene 
encodes one of the SHFV large envelope glycoproteins, then antisera against this 
glycoprotein should neutralize virus infectivity. Therefore, the monospecific murine anti- 
ORF 7 peptide sera was assayed for virus neutralization activity by the plaque inhibition 
assay. As expected, this antisera did exhibit neutralization activity with a titer of 80.
Taken together all of the above data suggests that the SHFV ORF 7 gene encodes one 
of the viral large envelope glycoproteins. This data is consistent with those of the other 
arteri viruses in which the third ORF from the 3' end of the genomes were identified as the 
respective large envelope glycoprotein genes.
3.5 Determination of the number of antigenic epitopes on the SHFV large envelope 
glycoprotein.
In order to determine the antigenic epitopes found on the SHFV large envelope 
glycoprotein it was necessary to produce monoclonal antibodies against the glycoprotein. 
Therefore, initial attempts involved inoculating mice with proteins from whole virus 
particles. After three inoculations of viral proteins, antiviral activity was detected in the 
mouse sera. Hybridomas were synthesized from the splenic cells of these mice, as described 
in Materials and Methods. mAbs produced by the hybridomas were screened by ELISA to 
detect SHFV reactivity; those determined to be positive were then screened by Western 
analysis to determine viral protein specificity. As shown in Table 6, eleven hybridomas were 
found and cloned. All of these hybridomas produced mAbs against the capsid, pl5, protein. 
Hybridomas producing mAbs directed against the viral envelope proteins were not identified.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
88
Table 6. ELISA values of supernatant fluids from hybridomas* producing mAbs to 



















‘Hybridomas were produced from mice immunized with purified SHFV particles.
'’ELISA values (O.D.450) were determined using undiluted supernatant fluid from hybridoma 
cultures.
The protein the mAb was directed against was determined by Western Blot analysis. 
dOver, O.D.4J0 * 2.0
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These data are not surprising, as the SHFV capsid protein appears to have the highest copy 
number of all the structural proteins in the virus particle.
Further investigations were needed to produce mAbs against the SHFV large 
envelope glycoprotein, p54. Since ORF 7 was identified as one of the p54 genes and 
polyclonal antiserum against the ORF 7 product was produced in mice using genetic 
immunizations, attempts were made to produce mAbs against the large envelope 
glycoprotein using genetic immunization of mice. Although anti-p54 serum was produced 
in these mice, initial attempts to produce mAb-producing hybridomas failed. Success was 
achieved, however, by im m u n i z i n g  the mice with SHFV proteins two weeks after the last 
genetic im m u n iz a t io n  boost. Hybridomas were screened by ELISA using whole virus protein 
initially followed by ORF 7 product alone. Using these methods, eight hybridomas 
producing mAbs against p54 were identified and cloned. These hybridomas were numbered 
p5F3-26, p6F7-6, pi 1C4-5, pl5F3-12, pl6A8-l 1, pl6F7-25, p33Dl-7 and p35F10-l. The 
mAbs produced by these hybridomas were isotyped (Table 7). It was determined that five 
of the eight hybridomas produced IgM antibodies. The antibodies produced by p5F3-26, 
pl6A8-l 1 and pl6F7-25 were IgGl, IgG2a and IgG3, respectively. Only kappa light chains 
were detected in the mAbs; none of the mAbs exhibited lambda light chains (Table 7).
In order to determine the number of antigenic epitopes on the p54 glycoprotein, 
competitive binding assays were performed using the anti-p54 mAbs. A first mAb was 
bound to SHFV proteins from purified virus particles. A second mAb, which was labeled 
with biotin was then allowed to bind to the viral proteins. Should both antibodies recognize 
the same antigenic or related epitope, then the first antibody will block the binding of the 
biotinylated antibody. ELISAs were performed to determine the amount of second antibody
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Table 7. Immunoglobulin isotyping of anti-p54 specific mAbs*
Isotype
IgA IeM IfiGl IgG2a IgG2b IgG3 K X
p5F3-26 — + — — — +
pllC4-5 — + — — — — +
pl5F3-12 — + — —  — — +
pl6A 8-ll — — — + — +
pl6F7-25 — — — — — + +
p6F7-6 — + — — — — +
p35F10-l — + — — — — +
p33Dl-7 — + — — +
aAnti-p54 mA )s were generated from hybridomas produced from mice genetically-
immunized with the SHFV ORF 7 gene.
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binding. As shown in Table 8, at least four epitopes could be delineated using this method. 
mAbs pi 1C4-5, p33Dl-7 and p35F10-l defined one epitope, p5F3-12 and p6F7-6 defined 
a second epitope and pl5F3-26 and pl6F7-25 defined a third epitope. pl6A8-l 1 was the 
only mAb to bind to a fourth epitope. None o f the mAbs completely inhibited the binding 
of the second antibody, even if both antibodies were the same (Table 8). Competitive 
inhibition in this assay was defined as positive if  the % Blocking Ability was greater than 
40%. All the negative values in this assay were 15% or lower (Table 8). It is not possible 
to unequivocally state that the blocking of binding of one antibody by another antibody is due 
to their recognizing the same epitope. It is possible that they recognize adjacent epitopes and 
that blockage of binding is due to steric hindrance. Therefore, this study shows that at least 
four antigenic epitopes were identified in the p54 glycoprotein.
Since the arteri viral GL glycoproteins are known to posses the virus neutralization 
sites, the anti-ORF 7 peptide mAbs were assayed for virus neutralization activity. 
Supernatant fluids containing one mAb directed against each of the four antigenic epitopes 
was used for this assay. Virus neutralizing activity was detected with neat supernatant fluid 
containing mAb p6F7-6. None of the other mAbs exhibited virus neutralization activity. 
These data suggest that the antigenic epitope as defined by mAbs p6F7-6 and p5F3-12 is a 
virus neutralization site.
3.6 Comparison of the ORF 7 gene sequence among different SHFV isolates.
Because the SHFV ORF 7 gene was shown to encode one of the viral large envelope 
glycoproteins and that this molecule contains at least four antigenic epitopes, the similarities/ 
differences in this gene sequence among different SHFV isolates was next determined. The 
genome sequence shown in figure 2 was derived from the prototype SHF virus, LVR, which
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Table 8. Competitive binding* of the anti-p54 mAbs
Biotinylated 2° mAb
1° rnAb PI1C4-S P33D1-7 p3SF10-l pSF3-12 p6F7-6 p!5F3-26 p!6F7-2S p !6A 8-ll
pllC4-5 5 9 b 42 68 0 9 3 2 0
p33Dl-7 44 7 9 61 10 0 11 5 15
p35F10-l 54 45 58 1 0 7 3 0
p5F3-12 12 0 0 55 63 6 0 0
p6F7-6 0 0 0 47 63 0 11 0
pl5F3-26 8 0 0 8 0 65 52 8
pl6F7-25 0 0 0 2 3 48 64 9
p!6A8-ll 6 13 0 0 4 4 7 53
"Competitive binding was assessed by binding concentrated 1 ° mAb to 0.05 |ig of purified 
SHFV proteins followed by the binding of the biotinylated 2 ° mAb. Binding of the 2 ° mAb 
was determined as O.D.4S0.
bCompetitive binding values are expressed as % Blocking Ability (see Materials and 
Methods)
Outlined box defines neutralizing epitope.
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was isolated from an NIH outbreak in 1964. Two additional virus isolates were available in 
the laboratory which were isolated from the 1989 New Mexico outbreak: one virus was 
isolated from a rhesus monkey and the second virus was isolated from a mouse. The ORF 
7 sequence of these New Mexico isolates were cloned, sequenced and compared to the LVR 
sequence. Since these isolates were separated from the prototype isolate by over 2,000 miles 
and 25 years, it was expected that the ORF 7 sequence would differ from the earlier 
sequence. Also, the glycoprotein encoded by this gene is exposed on the surface of the virus 
particle and should be under immunological stress which could result in mutations. 
Surprisingly, the ORF 7 gene from the New Mexico isolates was identical to the ORF 7 gene 
of the prototype isolate (Fig. 16). Interestingly, although no sequence difference was 
observed among different isolates, two nucleotide changes resulted in this gene by passing 
the virus through a primary rhesus monkey macrophage culture: position 31, C to T and 
position 243, T to C. The change at position 31 results in an amino acid substitution in the 
peptide from proline to a serine residue; the nucleotide change at position 243 is a silent 
mutation. Although a mutation resulting in a serine substitution for proline seems important, 
computer analysis of the glycoprotein suggests that this substitution would be within the 
signal sequence of the glycoprotein (Wisconsin Package Version 9.0, Genetics Computer 
Group (GCG), Madison, WI). Since signal sequences are cleaved from glycoproteins during 
synthesis, this substitution should not effect the confirmation of the viral glycoprotein.
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Figure 16: Comparison of the ORF 7 gene sequences from different SHFV isolates. 
LVR is the prototype SHFV isolate which was propagated in MAI04 cells. LVR/MAC 
is the prototype isolate passaged once in primary rhesus monkey macrophage cultures. 
The other two isolates were obtained from the 1989 SHFV outbreak in New Mexico. 
PH0080 was derived from a splenic homogenate from a rhesus monkey and 1-621 was 
isolated from the liver of a rhesus monkey after experimental inoculation of liver 
homogenate from a mouse trapped during the outbreak. Dashed lines represent 
nucleotide identity between the prototype and the other isolates.
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5 '
L V R : A T G T A C T TA TG TTTA G G G A G A TC G G A G A C TC C G TTG A TA G G TTT G TTC C G  5 0
1 - 6 2 1 :  ---------------------------------------------------------------------------------------------------------
P H 0 0 8 0 : ---------------------------------------------------------------------------------------------------------
LVR/MAC:  T ----------------------------------------
•  •  •  •  •
CACCTCATCTACATCTATCTCATGGTTCTATGTGCTTTTCTTTGTCTCTA 1 0 0
TTACATTCAGCAGCACCGGCGCATCCGAGAACAACACCGGTACGACCTGG 1 5 0
ATCAGCATATCAAAGTTTCCGTCATTGCTGCTGAGTCAGATCATAAGCCC 2 0 0
TAGTTACATTGTAAATATCTCTGTCTGTGGTGCATTTGACATTCAAAATA 2 5 0
ACACTCACTGGTTCACTCCTTGTAATTTGTCTGTCTTGAATCACTCTGAC 3 0 0
TGTCACACGTGTAAGTCAGAGCAGTCAAACCAATCTTTATTATCAAATTG 3 5 0
TTCAACGTGTTTCACACACCTTAGTTCTTGTTTTCTTCACACTTACACTG 4 0 0
(Figure 16, cont'd)
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GACACCACATCAATAACACTAGGCTTCTTTTAGAGACATATTTAGCAGTC 4 5 0
CCCTTACTAACCCATTTATTGAGTTATAAGTTTGCTACAACTGCCTCCTT 5 0 0
TCTTGACTTTGCCTTTTTTGCAGGACTTTCTATTACGGCCTATCGCTATG 5 5 0
TTTCACCGGCGATATTATTCTTCTTGCCACTCGCTCTCATCTTCTCGGCT 6 0 0
ATCTTCATCAAGAAGTTAGTGGTAAATTGTATGGCCCTCCGCTTCGCGTG 6 5 0
GACTAGGCACACCAATTTCATCATTGACGACCGAGGTAGATTATTTGTCA 7 0 0
ACCACGACGACGTGCTGATTTCCGACCCACAGGGACTGCGGGTTGGACCT 7 5 0
CATAAGGTCAGAGCCGCTAAGGTAATACTTGGTGGACGGGAGGCAAATTT 8 0 0
3 '
ACTCAGACAAGCACACGTCGAAGAGTGGTCATGGTAG 8 3 7
(Figure 16, cont’d)
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4. DISCUSSION
SHFV is a member of the virus family Arteriviridae within the newly formed virus 
order Nidovirales. This virus family contains only one genus, Arterivirus, which along with 
SHFV includes EAV, LDV, and PRRSV. The order Nidovirales includes a second virus 
family, the Coronaviridae. Members of the order Nidovirales share common genome 
organizations and replication strategies. Both phylogenetic analysis of individual conserved 
domains and comparison of genome organization strongly suggest that the arteri viruses and 
coronaviruses comprise a distinct evolutionary lineage among positive-strand RNA viruses. 
Unique features of this virus lineage are the location of the helicase domain on the C- 
terminal side of the polymerase domain and the presence of a conserved domain 4 in the 
ORF lb polyprotein. A less significant but characteristic feature is the presence of -SDD- 
sequence in place of the universal -GDD- signature sequence within the RNA-dependent 
RNA polymerase domain (Snijder and Spaan, 1995).
Morphologically, the arteriviruses differ markedly from the coronaviruses. First, 
coronaviruses gained their name from the large spike-like peplomers which protrude from 
the virion surface; these spike proteins were visualized by electron microscopy and were said 
to give the virus a “crown-like” or “corona” appearance (McIntosh, 1974). Spike-like 
structures are not visible on the arterivirus virions; instead, cup-like subunits have been 
observed (Brinton-Damell and Plagemann, 1975; Trousdale, et al., 1975). Second, the 
diameters of the arterivirus particles are approximately half that of the coronaviruses (Snijder 
and Spaan, 1995). Third, the nucleocapsids of the arteriviruses are icosahedral, while those 
of the coronaviruses are helical.
97
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
98
Among the four arteriviruses, the molecular characteristics of SHFV are the least 
known. In this report, the 3 ' end of the genome from the prototype isolate o f SHFV was 
cloned and sequenced. This sequence contains the 76 nt 3 ' noncoding region, all of the 3' 
ORFs and 1,590 nt of the SHFV ORF lb gene. Combining these sequence data with the 
SHFV ORF la/ lb sequence data obtained by M A  Brinton (unpublished data; Georgia State 
University, Atlanta, GA), the entire SHFV genome is estimated to be 15.7 kb in length. 
Thus, the SHFV genome is longer than the genomes of the other arteriviruses: 12.7 kb for 
EAV (den Boon, et al., 1991a), 14.2 kb for LDV (Godeny, et al., 1993), and 15.1 kb for 
PRRSV (Meulenberg, et al., 1993b).
The SHFV 3' ORFs were identified as ORFs 2a, 2b, 3,4, 5, 6,7, 8, and 9 moving 
from the 5' end to the 3 ' end and using conventional nomenclature (Cavanagh, et al., 1990). 
Perhaps the most striking feature of the SHFV genome sequence is the presence of three 
additional 3' ORFs; the SHFV genome contains nine 3 ' ORFs, whereas the genomes of 
EAV, LDV, and PRRSV contain six 3' ORFs. The ultimate and penultimate 3' ORFs 
encode the capsid and membrane proteins, respectively (de Vries, et al., 1992; Godeny, et al., 
1990; Meulenberg, et al., 1995). Similarly, the corresponding SHFV ORFs (ORFs 9 and 8) 
encode the same viral proteins (Godeny, et al., 1995). For EAV and LDV, ORFs 2 and 5 
have been shown to encode the small and large envelope glycoproteins, respectively (de 
Vries, et al., 1992; Faaberg and Plagemann, 1995). The PRRSV ORF 5 product was also 
shown to encode a glycoprotein but the ORF 2 product could not be detected in purified 
virions (Meulenberg, et al., 1995). In the present study, one of the SHFV large envelope 
glycoproteins (p54) was mapped to ORF 7. Similar to the EAV, LDV, and PRRSV ORFs 
5, the SHFV ORF 7 is the third ORF located from the 3 ' end of the viral genome.
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The ORFs 3 and 4 products of EAV, LDV, and PRRSV encode putative 
glycoproteins. The PRRSV ORFs 3 and 4 products were reported as viral envelope 
glycoproteins (van Nieuwstadt, et al., 1996). However, the corresponding gene products 
have not been detected in EAV or LDV particles. Although the gene products of the SHFV 
ORFs 2a through 6 remain unidentified, it was recently reported that small stretches of amino 
acid identity were found between some of these ORFs and ORFs from the other arteriviruses 
(Godeny, et al., 1998). The SHFV ORFs 2a and 4 products share a conserved amino acid 
sequence, -HPLG-, with the PRRSV ORF 2 product The conserved seven amino acid 
sequence -FHPELFG- was found in the SHFV ORF 2b product as well as the PRRSV ORF 
3 product Lastly, an -RWA- sequence was conserved in SHFV ORFs 3 and 6 and the 
PRRSV ORF 4 products. Computer-aided sequence comparisons did not detect significant 
sequence similarity between the ORF 5 product and any of the other SHFV proteins. 
However, both the number and distribution of cysteine residues in the ORF S encoded 
peptide was remarkably similar to those in the ORF 2b product Due to these sequence 
homologies and the positioning of conserved cysteine residues in the arteri viral 3' ORF 
products, it was proposed that the SHFV ORFs 2a through 6 were related to the EAV, LDV, 
and PRRSV ORFs 2 through 4 products (Godeny, et al., 1998). Further, it was postulated 
that the SHFV ORFs 4 through 6 might have been generated through a heterologous RNA 
recombination event during which ORFs 2a, 2b and 3 were duplicated (Godeny, et al., 1998). 
Further support for a recombination event can be found in the overlap regions of the 3' 
ORFs. All but two of the SHFV ORFs overlap their adjacent 5' ORFs (Smith, et al., 1997); 
there is a noncoding gap of 42 nt between ORFs 3 and 4, and a 5 nt gap between ORFs 6 and
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7. These gaps suggest that the RNA encoding ORFs 4 through 6 may have been placed 
between existing overlapping ORFs.
During replication, arteriviruses produce sets of sgRNAs which are nested and 3 ' co­
terminal (reviewed in de Vries, et al., 1997 and Snijder and Meulenberg, 1998). The 
sgRNAs each contain a 5' leader sequence which is joined to the body of the sgRNA by a 
conserved junction sequence (de Vries, et al., 1997; Snijder and Spaan, 1995). The overall 
SHFV junction sequence is 5'-UCNUUAACC-3 ' in which only the residues at position 7 and 
8 are strictly conserved. This junction sequence is similar to those found for the other 
arteriviruses: 5'-UCAAC(U/C)-3' for EAV (den Boon, et al., 1996), 5'-U(A/G)(U/A)AACC- 
3' for LDV (Godeny, et al., 1993; Kuo, et al., 1992), and 5'-GNUNAACC-3' for PRRSV 
(Conzelmann, et al., 1993; Meulenberg, et al., 1993a). The 3' nucleotides of the LDV, 
PRRSV, and EAV junction sequences are conserved as 5'-AAC(U/C)-3\ Indeed, this 
sequence motif appeared in six of the eight SHFV junction sequences (Fig.4). Although the 
conserved junction sequence of SHFV is similar to those of the other arteriviruses, it appears 
to be longer and shows less nucleotide conservation. Unlike the other arteri viral junction 
sequences which are rich in adenine and uridine (Snijder and Spaan, 1995), the SHFV 
junction sequence is rich in uridine and cytidine residues.
Northern blot analysis of cytoplasmic RNAs from SHFV infected cells revealed that 
six sgRNAs, estimated at 4.7,3.3,2.7,2.0,12 , and 0.65 kb in lengths, were produced during 
virus replication (Godeny, et al., 1995; Zeng, et al., 1995). Because one sgRNA is produced 
for each of the arteri viral 3' ORFs (Snijder and Spaan, 1995) and SHFV encodes nine 3' 
ORFs, it was expected that SHFV should produce nine sgRNAs. However, the junction 
sequence data suggests that SHFV produces eight sgRNAs during replication, in contrast
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with the other three arteriviruses which produce six to seven sgRNAs during replication 
(Kuo, et al., 1992; Meulenberg, et al., 1993a; van Berio, et al., 1986). These SHFV sgRNAs 
were numbered RNAs 2 ,3 ,4 ,5 , 6, 7, 8, and 9 and their sizes were predicted to be 5.049, 
4.032, 3.454,2.827, 2.642,1.921,1.210, and 0.629 kb in length, respectively. Except for 
RNAs 3 and 5, the lengths of the SHFV sgRNAs correspond to the estimated sizes of the 
previously reported six sgRNAs (Godeny, et al., 1995; Zeng, et al., 1995). Interestingly, the 
junction sequence amplicons from RNAs 3 and 5 were always lower in concentration than 
those of the other six sgRNAs suggesting that these two RNAs are produced in low amounts 
during viral replication and may, in fact, be synthesized at levels too low to be detected by 
Northern blot hybridization. This could explain why these sgRNAs were previously 
overlooked.
Since SHFV produces eight sgRNAs, it is presumed that at least eight of the nine 
SHFV 3' ORFs are functional. ORF 2b was found to lack a unique junction sequence 
suggesting that this gene may be silent. However, since icosahedral RNA viruses do not 
usually encode silent genes, another possibility is that RNA 2 is polycistronic; both ORFs 
2a and 2b may be translated from RNA 2. Although the coronaviruses are known to 
synthesize polycistronic sgRNA (de Vries, et al., 1997, Cavanagh, et al., 1994, Siddell, 
1995), SHFV is the first arterivirus presenting two ORFs on one sgRNA only. Since this 
SHFV ORF 2a/ 2b phenomenon was reported (Godeny, et al., 1998), a second ORF (ORF 
2a on EAV, LDV, and PRRSV and ORF 4a on SHFV) was identified which would make the 
EAV, LDV and PRRSV RNAs 2 and the SHFV RNA 4 polycistonic (de Vries and Snijder, 
personal communication). These new arterivirus ORFs encode a small (60 to 80 amino acids
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in length), hydrophobic protein similar to the coronavirus E protein (Cavanagh, et al., 1994; 
Spaan, et al., 1988).
It was previously reported that SHFV encodes at least four structural proteins, plS, 
p20, p42, and p54 (Godeny, et al., 1995). In the present study, the p42 and p54 glycoproteins 
were shown to consist of at least four glycoproteins which comigrate. These glycoproteins 
have peptide backbones ranging in mass between 28 and 30 kDa. These data suggests that 
at least six structural proteins make up the SHF virion particle. One of the p54 glycoproteins 
mapped to ORF 7 on the SHFV genome. This result was expected because of the high 
number of potential N-linked glycosylation sites encoded by this ORF and the 
hydrophobicity pattern of the ORF 7 product which was similar to those of the other 
arteri viral GL proteins. Since there are nine 3' ORFs on the SHFV genome, the potential 
exists for nine SHFV structural proteins. Until all of the SHFV 3' ORFs are expressed and 
their products mapped to the genome it can not be determined if the additional three ORFs 
encode nonstructural proteins, as yet unidentified structural proteins, or if the genes are 
silent
Protein analysis studies indicated that the GL proteins of LDV, EAV, and PRRSV 
exhibit a similar and rather unique structure, despite considerable amino acid divergence (de 
Vries, et al., 1992; den Boon, et al., 1991b; Faaberg and Plagemann, 1995; Meulenberg, et 
al., 1995). These GL proteins possess a potential signal peptide and three potential internal 
transmembrane segments, although it is not known if this internal hydrophobic domain spans 
the viral envelope one or three times. In the LDV GL protein, an ectodomain of about 30 
amino acids was predicted to project externally from the viral envelope after signal sequence 
cleavage (Faaberg and Plagemann, 1995). This LDV ectodomain possesses three potential
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N-linked glycosyladon sites. In contrast, an ectodomain of about 95 amino acids is proposed 
for the EAV GL protein. The EAV ectodomain contains a single polylactosaminoglycan side 
chain (de Vries, et al., 1992; den Boon, et al., 1991b). Because the hydrophobicity pattern 
for the SHFV ORF 7 peptide is consistent with those of the EAV, LDV, and PRRSV GL 
proteins, it is presumed that it possesses a similar membrane topography. Indeed, the 
predicted signal sequence cleavage site for the SHFV ORF 7 peptide is at amino acid 41. If 
this signal cleavage site were used, an ectodomain of approximately 100 amino acids would 
remain before the transmembrane region. All of the eight potential N-linked glycosyladon 
sites encoded in this protein are found within this ectodomain region.
The arteri viral GL proteins are important vital structural proteins; they are the major 
envelope glycoproteins found on the surface of the viral particles. The EAV and LDV GL 
proteins were found linked to the viral M proteins in intact virions (de Vries, et al., 1992; 
Faaberg and Plagemann, 1995). This linkage was shown to result via disulfide bonds in 
LDV (Faaberg and Plagemann, 1995). Further, the PRRSV GL protein was shown to induce 
apoptosis when expressed as a vaccinia virus recombinant (Suarez, et al., 1996a). However, 
the relevance of this property for infection and pathogenesis is not known.
All known neutralizing antibodies produced against any of the arteriviruses react with 
the respective viral GL protein (Balasuriya, et al., 1993; Coutelier and van Snick, 1988; 
Deregt, et al., 1994; Glaser, et al., 1995; Harty, et al., 1987; Pirzadeh and Dea, 1997). Since 
neutralizing activity can be mapped to the arterivirus GL protein, it has been suggested that 
this viral envelope glycoprotein may be involved in binding of the virus to the receptor on 
the cell. Neutralizing anti-EAV mAbs bind to the putative ectodomain, amino acids 19
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through 115, of the GL protein (Balasuriya, et ai., 1997). Further, neutralization escape 
mutants of EAV contained mutations or deletions in the amino-terminal ectodomain of this 
glycoprotein (Balasuriya, et al., 1997; Balasuriya, et al., 1995b; Glaser, et al., 1995). The 
major neutralizing epitope of LDV was also mapped to the putative ectodomain of the GL 
glycoprotein (Li, et al., 1998). The neutralising  epitopes on the SHFV GL protein have not 
been mapped. In this report, four putative antigenic epitopes were identified on the SHFV 
ORF 7 glycoprotein, GL, using mAbs. Because one of these mAbs also exhibits virus 
neutralizing activity, it can be inferred that one of these four epitopes comprises a virus 
neutralization site. It remains to be determined if any or all of these antigenic epitopes map 
to the putative ectodomain on the SHFV GL glycoprotein.
Amino acid sequence comparisons of the capsid and membrane proteins have 
suggested that LDV, PRRSV and SHFV are more similar to each other than they are to EAV 
(Godeny, et al., 1995; Snijder and Meulenberg, 1998). The capsid protein of SHFV shows 
little similarity to the other arteriviruses. This SHFV protein showed a 39%, 39% and 41% 
sequence similarity with the capsid proteins of EAV, LDV and PRRSV, respectively 
(Godeny, et al., 1995). Whereas the amino acid similarity between the capsid proteins of 
EAV and LDV was 47%, EAV and PRRSV was 42%, and LDV and PRRSV was 57%. The 
arteriviral membrane proteins are more conserved than the capsid proteins. The amino acid 
sequence similarity between the M proteins of EAV and LDV was 44%, between EAV and 
PRRSV was 47%, and LDV and PRRSV was 70%. The SHFV membrane protein exhibited 
48% similarity with the EAV protein, 54% similarity with the LDV protein, and 57% 
similarity with the PRRSV protein (Godeny, et al., 1995). The SHFV GL protein shares 43%,
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53%, and 57% sequence similarity with the GL proteins of EAV, LDV, and PRRSV, 
respectively. These GL protein sequence comparisons further substantiate the phylogenetic 
relationship between LDV, PRRSV, and SHFV.
Since the arteri viral GL glycoproteins are thought to project from the surface of the 
viral envelope it is expected that they would encounter a high degree of immunological 
pressure. Therefore a reasonable amount of amino acid sequence divergence would be 
expected to appear among different isolates of arteriviruses. Indeed, field isolates o f EAV 
exhibited between 89.8% and 99.6% identity within the GL peptide sequence (Balasuriya, 
et al., 1995a; Glaser, et al., 1995). A study of different European and North American 
isolates of PRRSV showed that the GL envelope glycoprotein was the most heterologous 
polypeptide of the viral structural proteins (Balasuriya, et al., 1995a; Mardassi, et al., 1995; 
Suarez, et al., 1996b). Therefore, it was quite surprising that no differences were observed 
in the SHFV GL amino acid sequence among the prototype isolate (a laboratory strain first 
isolated in 1964 from an infected rhesus monkey) and two isolated from the 1989 New 
Mexico outbreak, especially since one of the New Mexico isolates was isolated from a mouse 
and not a monkey. This conservation of the SHFV GL peptide sequence suggests that few 
alterations in this glycoprotein are tolerated for virus survival. Additional isolates need to 
be examined in order to substantiate this hypothesis because of the low number o f SHFV 
isolates compared in this study,.
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5. SUMMARY AND CONCLUSIONS
The 3' end of the genome from the prototype isolate of SHFV was successfully 
cloned and sequenced. The SHFV genome contains nine 3 ' ORFs, which were identified as 
ORFs 2a, 2b, 3, 4,5, 6, 7, 8, 9 moving from the 5' end to 3' end of the genome using 
conventional nomenclature. Compared with the genomes of other arteriviruses, SHFV 
contains three additional ORFs. The SHFV 3 ' end sequence contains the 76 nt 3' noncoding 
region, all of the 3' ORFs and 1,590 nt of the SHFV ORF lb gene.
SHFV produces eight sgRNAs during replication, in contrast with the other three 
arteriviruses, which produce six to seven sgRNAs during replication. These SHFV sgRNAs 
were numbered as 2 ,3 ,4 , 5, 6, 7, 8, and 9. Their sizes were determined to be 5.049,4.032, 
3.454, 2.827, 2.642, 1.921, 1.210, and 0.629 kb in length, respectively. The arteriviral 
sgRNAs are composed of a 5' leader sequence which is joined to the body of the mRNA 
through a conserved junction sequence. The overall SHFV junction sequence is 5'- 
UCNUUAACC-3' in which only the residues at position 7 and 8 are strictly conserved. The 
conserved j unction sequence of SHFV is similar to those of the other arteriviruses. However, 
the SHFV junction sequence appears to be longer and shows less nucleotide conservation 
than those of the other arteriviruses.
It was previously reported that the SHFV particle was made up of at least two 
structural proteins, pi 5 and p20, and two structural glycoproteins, p54 and p42. In the 
present study it was found that p42 and p54 are actually four glycoproteins which comigrate 
by SDS-PAGE. These glycoproteins have peptide backbones ranging in mass between 28 
and 30 kDa after digesting by endoglycosidase F. These peptides reacted with specific
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polyclonal antiserum against SHFV by Western blot analysis. Combining these data with 
the previously reported number of proteins within the SHFV particle, the SHF virion particle 
consists of at least six structural proteins.
Immunoprecipitation studies using the in vitro expressed SHFV ORF 7 product 
proved that this gene encodes one of the SHFV large envelope glycoproteins, GL. This result 
was expected because of the high number of potential N-linked glycosylation sites encoded 
by this ORF and the hydrophobicity pattern of this gene product which was similar to those 
of the other arteri viral GL proteins. Similar to the EAV, LDV and PRRSV ORFs 5, the 
SHFV ORF 7 is the third ORF located from the 3' end of the viral genome.
Eight mAbs were produced by genetic immunizations of mice with the SHFV ORF 
7 gene. These mAbs were used to delineate four antigenic epitopes on the SHFV ORF 7 
glycoprotein. Because one of these mAbs also exhibits virus neutralizing activity, it can be 
inferred that one of these four epitopes comprises a virus neutralization site.
The ORF 7 genes from two additional SHFV isolates were cloned, sequenced, and 
compared to that of the prototype SHFV isolate. Surprisingly, no differences were observed 
in SHFV Gl amino acid sequence among the prototype isolate and the two isolates from the 
1989 New Mexico outbreak.
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